

Multi-scale Inference of Genetic Trait Architecture using Biologically Annotated Neural Networks

Pinar Demetci^{1,2,*}, Wei Cheng^{2,3,*}, Gregory Darnell^{2,4}, Xiang Zhou^{5,6}, Sohini Ramachandran¹⁻³, and Lorin Crawford^{2,7,8,†}

1 Department of Computer Science, Brown University, Providence, RI, USA

2 Center for Computational Molecular Biology, Brown University, Providence, RI, USA

3 Department of Ecology and Evolutionary Biology, Brown University, Providence, RI, USA

4 Institute for Computational and Experimental Research in Mathematics (ICERM), Brown University, Providence, RI, USA

5 Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA

6 Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA

7 Department of Biostatistics, Brown University, Providence, RI, USA

8 Center for Statistical Sciences, Brown University, Providence, RI, USA

* Authors Contributed Equally

† Corresponding E-mail: lorin_crawford@brown.edu

Abstract

Here, we present Biologically Annotated Neural Networks (BANNs), a novel probabilistic framework that makes machine learning fully amenable for GWA applications. BANNs are feedforward models with partially connected architectures that are based on biological annotations. This setup yields a fully interpretable neural network where the input layer encodes SNP-level effects, and the hidden layer models the aggregated effects among SNP-sets. Part of our key innovation is to treat the weights and connections of the network as random variables with prior distributions that reflect how genetic effects manifest at different genomic scales. The BANNs software uses scalable variational inference to provide fully interpretable posterior summaries which allow researchers to *simultaneously* perform (i) fine-mapping with SNPs and (ii) enrichment analyses with SNP-sets on complex traits. Through simulations, we show that our method improves upon state-of-the-art fine mapping and enrichment approaches across a wide range of genetic architectures. We then further illustrate the benefits of BANNs by analyzing real GWA data assayed in approximately 2,000 heterogenous stock of mice from Wellcome Trust Centre for Human Genetics and approximately 7,000 individuals from the Framingham Heart Study. Lastly, using a subset of individuals of European ancestry from the UK Biobank, we show that BANNs is able to replicate known associations that required functional validation using statistics alone.

Introduction

Over the two last decades, a considerable amount of methodological research in statistical genetics has focused on developing and improving the utility of linear mixed models (LMMs) [1–13]. The flexibility and interpretability of LMMs make them a widely used tool in genome-wide association (GWA) studies, where the goal is to test for associations between individual single nucleotide polymorphisms (SNPs) and a phenotype of interest. In these cases, traditional LMMs provide a set of P -values or posterior inclusion probabilities (PIPs) which lend statistical evidence on how important each variant is for explaining the overall genetic architecture of a trait. However, this univariate SNP-level approach is underpowered for “polygenic” traits which are generated by many mutations of small effect [14–19]. To mitigate this

43 issue, more recent work has extended the LMM framework to identify enriched gene or pathway-level
44 associations, where SNPs within a particular genomic region are combined (commonly known as a SNP-
45 set) to detect biologically relevant disease mechanisms underlying the trait [20–27]. Still, the performance
46 of standard SNP-set methods can be hampered by strict additive modeling assumptions; and the most
47 powerful of these LMM approaches rely on algorithms that are computationally inefficient and unreliable
48 for large-scale sets of data [28].

49 The explosion of large-scale genomic datasets has provided the unique opportunity to move beyond
50 the traditional LMM framework and integrate machine learning techniques as standard statistical tools
51 within GWA analyses. Indeed, machine learning methods such as neural networks are well known to
52 be most powered in settings when large training data is available [29]. This includes GWA applications
53 where consortiums have data sets that include hundreds of thousands of individuals genotyped at millions
54 of markers and phenotyped for thousands of traits [30]. It is also well known that these nonlinear
55 statistical approaches often exhibit greater predictive accuracy than LMMs, particularly for complex
56 traits with broad-sense heritability that is driven by non-additive genetic variation (e.g., gene-by-gene
57 interactions) [31]. One of the key characteristics that leads to better predictive performance from machine
58 learning approaches is the automatic inclusion of higher order interactions between variables being put
59 into the model [32, 33]. For example, neural networks leverage nonlinear activation functions between
60 layers that implicitly enumerate all possible (polynomial) interaction effects [34]. While this is a partial
61 mathematical explanation for model improvement, in many biological applications, we often wish to
62 know precisely which subsets of variants are most important in defining the architecture of a trait.
63 Unfortunately, the classic statistical idea of variable selection and hypothesis testing is lost within machine
64 learning methods since they do not naturally produce interpretable significance measures (e.g., P -values
65 or PIPs) like traditional LMMs [33, 35].

66 In this work, we develop biologically annotated neural networks (BANNs), a novel probabilistic frame-
67 work that makes machine learning amenable for fine mapping and discovery in high-dimensional genomic
68 association studies (Fig. 1). BANNs are feedforward Bayesian models with partially connected architec-
69 tures that are guided by predefined SNP-set annotations (Fig. 1a). Our approach produces three key
70 scientific contributions. First, the partially connected network architecture yields a fully interpretable
71 model where the input layer encodes SNP-level effects, and the single hidden layer models the effects
72 among SNP-sets (Fig. 1b). Second, we treat the weights and connections of the network as random
73 variables with sparse prior distributions, which flexibly allows us to model a wide range of sparse and
74 polygenic genetic architectures (Fig. 1c). Third, we perform an integrative model fitting procedure where
75 the enrichment of SNP-sets in the hidden layer are directly influenced by the distribution of associated
76 SNPs with nonzero effects on the input layer. These three components make for a powerful machine
77 learning strategy for conducting fine mapping and enrichment analyses simultaneously on complex traits.
78 With detailed simulations, we assess the power of BANNs to identify significant SNPs and SNP-sets
79 under a variety of genetic architectures, and compare its performance against multiple competing ap-
80 proaches [21, 23, 25–27, 36–39]. We also apply the BANNs framework to six quantitative traits assayed in
81 a heterogenous stock of mice from Wellcome Trust Centre for Human Genetics [40], and two quantitative
82 traits in individuals from the Framingham Heart Study [41]. For the latter, we include a replication study
83 where we independently analyze the same traits in a subset of individuals of European ancestry from the
84 UK Biobank [30].

85 Results

86 BANNs Framework Overview

87 Biologically annotated neural networks (BANNs) are feedforward models with partially connected archi-
88 tures that are inspired by the hierarchical nature of biological enrichment analyses in GWA studies

89 (Fig. 1). The BANNs framework simply requires individual-level genotype/phenotype data and a pre-
90 defined list of SNP-set annotations (Fig. 1a). The method can also take in summary statistics where
91 SNP-level effect size estimates are treated as the phenotype and an estimate of the linkage disequilibrium
92 (LD) matrix is used as input data (Supplementary Fig. 1). Structurally, sequential layers of the
93 BANNs model represent different scales of genomic units. The first layer of the network takes SNPs as
94 inputs, with each unit corresponding to information about a single SNP. The second layer of the net-
95 work represents SNP-sets. All SNPs that have been annotated for the same SNP-set are then connected
96 to the same neuron in the second layer (Fig. 1b). In this work, we define SNP-sets as collections of
97 functionally interacting variants that fall within a chromosomal window or neighborhood. For example,
98 when studying human GWA data, we use gene annotations as defined by the NCBI's Reference Sequence
99 (RefSeq) database in the UCSC Genome Browser [42] (Methods). The BANNs framework flexibly allows
100 for overlapping annotations. In this way, SNPs may be connected to multiple hidden layer units if they
101 are located within the intersection of multiple gene boundaries. SNPs that are unannotated, but located
102 within the same genomic region, are connected to their own units in the second layer and represent the
103 intergenic region between two annotated genes. Given the natural biological interpretation of both layers,
104 the partially connected architecture of the BANNs model creates a unified framework for comprehensi-
105 bly understanding SNP and SNP-set level contributions to the broad-sense heritability of complex traits
106 and phenotypes. Notably, this framework may be easily extended to other biological annotations and
107 applications.

108 We frame the BANNs methodology as a Bayesian nonlinear mixed model with which we can perform
109 classic variable selection (Fig. 1c; see Methods). Here, we leverage the fact that using nonlinear activation
110 functions for the neurons in the hidden layer implicitly accounts for both additive and non-additive effects
111 between SNPs within a given SNP-set (Supplementary Notes). Part of our key innovation is to treat the
112 weights and connections of the neural network as random variables with prior distributions that reflect
113 how genetic effects are manifested at different genomic scales. For the input layer, we assume that the
114 effect size distribution of non-null SNPs can take vastly different forms depending on both the degree and
115 nature of trait polygenicity [28]. For example, polygenic traits are generated by many mutations of small
116 effect, while other phenotypes can be driven by just a few clusters of SNPs with effect sizes much larger
117 in magnitude [19]. To this end, we place a normal mixture prior on the input layer weights (θ) to flexibly
118 estimate a wide range of SNP-level effect size distributions [10, 43–45]. Similarly, we follow previous
119 works and assume that enriched SNP-sets contain at least one SNP with a nonzero effect on the trait of
120 interest [26]. This is formulated by placing a spike and slab prior on the weights in the second layer (w).
121 With these point mass mixture distributions, we assume that each connection in the neural network has
122 a nonzero weight with: (i) probability π_θ for SNP-to-SNP-set connections, and (ii) probability π_w for
123 SNP-set-to-phenotype connections. By modifying a widely used variational inference algorithm for neural
124 networks [46], we jointly infer posterior inclusion probabilities (PIPs) for SNPs (γ_θ) and SNP-sets (γ_w).
125 The PIPs are defined as the posterior probability that the weight of a given connection is nonzero. We
126 use this information to prioritize statistically associated SNPs and SNP-sets that significantly contribute
127 to the broad-sense heritability of the trait of interest. With biologically annotated units and the ability
128 to perform statistical inference on explicitly defined parameters, our model presents a fully interpretable
129 extension of neural networks to GWA applications. Details and derivations of the BANNs framework can
130 be found in Methods and Supplementary Notes.

131 Power to Detect SNPs and SNP-Sets in Simulation Studies

132 In order to assess the performance of models under the BANNs framework, we simulated complex traits
133 under multiple genetic architectures using real genotype data on chromosome 1 from ten thousand ran-
134 domly sampled individuals of European ancestry in the UK Biobank [30] (see Methods and previous
135 work [9, 28]). After quality control procedures, our simulations included 36,518 SNPs (Supplemen-
136 tary Notes). Next, we used the NCBI's Reference Sequence (RefSeq) database in the UCSC Genome

137 Browser [42] to annotate SNPs with the appropriate genes. Unannotated SNPs located within the same
138 genomic region were labeled as being within the “intergenic region” between two genes. Altogether, this
139 left a total of $G = 2,816$ SNP-sets to be included in the simulation study.

140 After the annotation step, we assume a linear model to generate quantitative traits while varying
141 the following parameters: broad-sense heritability ($H^2 = 0.2$ and 0.6); the proportion of broad-sense
142 heritability that is being contributed by additive effects versus pairwise *cis*-interaction effects ($\rho = 1$ and
143 0.5); and the percentage of enriched SNP-sets that influence the trait (set to 1% for sparse and 10% for
144 polygenic architectures, respectively). We use the parameter ρ to assess the neural network’s robustness
145 in the presence of non-additive genetic effects between causal SNPs. To this end, $\rho = 1$ represents
146 the limiting case where the variation of a trait is driven by solely additive effects. For $\rho = 0.5$, the
147 additive and pairwise interaction effects are assumed to equally contribute to the phenotypic variance.
148 In each scenario, we consider traits being generated with and without additional population structure
149 (Methods). In the former setting, traits are simulated while also using the top ten principal components
150 of the genotype matrix as covariates to create stratification. The genetic contributions of the principal
151 components are fixed to be 10% of the total phenotypic variance. Throughout this section, we assess the
152 performance for two versions of the BANNs framework. The first takes in individual-level genotype and
153 phenotype data; while, the second models GWA summary statistics (hereafter referred to as BANN-SS).
154 For the latter, GWA summary statistics are computed by fitting a single-SNP univariate linear model (via
155 ordinary least squares) without any control for polygenic effects. All results are based on 100 different
156 simulated phenotypes for each parameter combination (Supplementary Notes).

157 The main utility of the BANNs framework is having the ability to detect associated SNPs and enriched
158 SNP-sets *simultaneously*. Therefore, we compare the performance of BANNs to state-of-the-art SNP
159 and SNP-set level approaches [21, 23, 25–27, 36–39], with the primary idea that our method should be
160 competitive in both settings. For each method, we assess the empirical power and false discovery rates
161 (FDR) for identifying either the correct causal SNPs or the correct SNP-sets containing causal SNPs
162 (Supplementary Tables 1-8). Frequentist approaches are evaluated at a Bonferroni-corrected threshold
163 for multiple hypothesis testing (e.g., $P = 0.05/36518 = 1.37 \times 10^{-6}$ at the SNP-level and $P = 0.05/2816$
164 $= 1.78 \times 10^{-5}$ at the SNP-set level, respectively); while, Bayesian methods are evaluated according to the
165 median probability model (PIPs and posterior enrichment probability ≥ 0.5) [47]. We also compare each
166 method’s ability to rank true positives over false positives via receiver operating characteristic (ROC)
167 and precision-recall curves (Fig. 2 and Supplementary Figs. 2-16). Specific results about these analyses
168 are given below.

169 **Fine Mapped SNP-Level Results.** For SNP-level comparisons, we used three fine-mapping methods
170 as benchmarks: CAVIAR [38], SuSiE [39], and FINEMAP [37]. Each of these methods implement
171 Bayesian variable selection strategies, in which different sparse prior distributions are placed on the “true”
172 effect sizes of each SNP and posterior inclusion probabilities (PIPs) are used to summarize their statistical
173 relevance to the trait of interest. Notably, both CAVIAR (exhaustively) and FINEMAP (approximately)
174 search over different models to find the best combination of associated SNPs with nonzero effects on
175 a given phenotype. On the other hand, the software for SuSiE requires an input ℓ which fixes the
176 maximum number of causal SNPs to include in the model. In this section, we consider results when this
177 input number is high ($\ell = 3000$) and when this input number is low ($\ell = 10$). While SuSiE is applied to
178 individual-level data, both CAVIAR and FINEMAP require summary statistics where marginal z-scores
179 are treated as a phenotype and modeled with an empirical estimate of the LD matrix.

180 Overall, BANNs, BANN-SS, and SuSiE (with high $\ell = 3000$) consistently achieve the greatest empir-
181 ical power and lowest FDR across all genetic architectures we considered. These three approaches also
182 stand out in terms of true-versus-false positive rates and precision-versus-recall. Notably, the choice of
183 the ℓ parameter largely influenced the performance of SuSiE, as it was consistently the worst performing
184 method when we underestimated the number of causal SNPs with nonzero effects *a priori* (i.e., $\ell = 10$).

185 Importantly, these performance gains come with a cost: the computational run time of SuSiE becomes
186 much slower as ℓ increases (Supplementary Table 9). For more context, an analysis on just 4,000 indi-
187 viduals and 10,000 SNPs takes the BANNs methods an average of 319 seconds to run on a CPU; while,
188 SuSiE can take up to nearly twice as long to complete as ℓ increases (e.g., average runtimes of 23 and
189 750 seconds for $\ell = 10$ and 3000, respectively).

190 Training BANNs on individual-level data clearly becomes the best approach when the broad-sense
191 heritability of complex traits is partly made up of pairwise genetic interaction effects between causal SNPs
192 (e.g., $\rho = 0.5$; see Supplementary Figs. 5-8 and 13-16)—particularly when traits have low heritability
193 with polygenic architectures (e.g., $H^2 = 0.2$). A direct comparison of the PIPs derived by BANNs and
194 SuSiE shows that the integrative and nonlinear neural network training procedure of BANNs enables
195 its ability to identify associated SNPs even in these more complex phenotypic architectures (Fig. 3 and
196 Supplementary Figs. 17-23). Ultimately, this result is enabled by the ReLU activation functions in the
197 hidden layers of the BANNs framework, which implicitly enumerates the interactions between SNPs within
198 the a given SNP-set (Supplementary Notes). The BANN-SS, CAVIAR, and FINEMAP methods see a
199 decline in performance for these same scenarios with genetic interactions. Assuming that the additive
200 and non-additive genetic effects are uncorrelated, this result is also expected since summary statistics are
201 often derived from simple linear additive regression models that (in theory) partition or marginalize out
202 proportions of the phenotypic variance that are contributed by nonlinearities [9, 13].

203 **Enriched SNP-Set Level Results.** For comparisons between SNP-set level methods, we consider
204 six gene or SNP-set enrichment approaches including: RSS [26], PEGASUS [25], GBJ [27], SKAT [21],
205 GSEA [36], and MAGMA [23]. SKAT, VEGAS, and PEGASUS fall within the same class of frequentist
206 approaches, in which SNP-set GWA P -values are assumed to be drawn from a correlated chi-squared
207 distribution with covariance estimated using an empirical LD matrix [48]. MAGMA is also a frequentist
208 approach in which gene-level P -values are derived from distributions of SNP-level effect sizes using an
209 F -test [23]. GBJ attempts to improve upon the previously mentioned methods by generalizing the Berk-
210 Jones statistic to account for complex correlation structures and adaptively adjust the size of annotated
211 SNP-sets to only SNPs that maximize power [49]. Lastly, RSS is a Bayesian linear mixed model enrich-
212 ment method which places a likelihood on the observed SNP-level GWA effect sizes (using their standard
213 errors and LD estimates), and assumes a spike-and-slab shrinkage prior on the true SNP effects to derive
214 a probability of enrichment for genes or other annotated units [50]. It is worth noting that, while RSS
215 and the BANNs framework are conceptually different, the two methods utilize very similar variational
216 approximation algorithms for posterior inference [46] (Methods and Supplementary Notes).

217 Similar to the conclusions drawn during the SNP-level assessments, both the BANNs and BANN-SS
218 implementations had among the best tradeoffs between true and false positive rates for detecting enriched
219 SNP-sets across all simulations—once again, including those scenarios which also considered pairwise
220 interactions between causal SNPs. Since RSS is an additive model, it sees a decline in performance
221 for the more complex genetic architectures that we simulated. A direct comparison between the PIPs
222 from BANNs and RSS can be found in Fig. 3 and Supplementary Figs. 17-23. While RSS also performs
223 generally well for the additive trait architectures, the algorithm for the model often takes twice as long
224 than either of the BANNs implementations to converge (Supplementary Table 10). PEGASUS, GBJ,
225 SKAT, and MAGMA are score-based methods and, thus, are expected to take the least amount of time to
226 run. BANNs and RSS are hierarchical regression-based methods and the increased computational burden
227 of these approaches results from their need to do (approximate) Bayesian posterior inference; however,
228 the sparse and partially connected architecture of the BANNs framework allows it to scale more favorably
229 for larger dimensional datasets. Previous work has suggested that when using GWA summary statistics
230 to identify genotype-phenotype associations at the SNP-set level, having the ability to adaptively account
231 for possibly inflated SNP-level effect sizes and/or P -values is crucial [28]. Therefore, it is understandable
232 why the score-based methods consistently struggle relative to the regression-based approaches even in

233 the simplest simulation cases where traits are generated to have high broad-sense heritability, sparse
234 phenotypic architectures that are dominated by additive genetic effects, and total phenotypic variance
235 that is not confounded by additional population stratification (Fig. 2 and Supplementary Figs. 2-16).
236 Both the BANN-SS and RSS methods use shrinkage priors to correct for potential inflation in GWA
237 summary statistics and recover estimates that are better correlated with the true generative model for
238 the trait of interest.

239 **Estimating Total Phenotypic Variance Explained in Simulation Studies.**

240 While our main focus is on conducting multi-scale inference of genetic trait architecture, because the
241 BANNs framework provides posterior estimates for all weights in the neural network, we are able to also
242 provide an estimate of phenotypic variance explained (PVE). Here, we define PVE as the total proportion
243 of phenotypic variance that is explained by fixed genetic effects (both additive and non-additive) and
244 random effects (e.g., population stratification), collectively [16]. Within the BANNs framework, this
245 estimation can be done on both the SNP and SNP-set level while using either genotype-phenotype data
246 or summary statistics (Supplementary Notes). For our simulation studies, the true $PVE = H^2 + 10\%$
247 and H^2 for traits generated with and without including the top ten genotypic principal components
248 as covariates, respectively. We assess the ability of BANNs to recover these true estimates using root
249 mean square error (RMSE) (Supplementary Figs. 24 and 25). In order to be successful at this task,
250 the neural network needs to accurately estimate both the individual effects of causal SNPs in the input
251 layer, as well as their cumulative effects for SNP-sets in the outer layer. BANNs and BANN-SS exhibit
252 the most success with traits have additive sparse architectures (with and without additional population
253 structure)—achieving PVE estimates with RMSEs as low as 4.54×10^{-3} and 4.78×10^{-3} on the SNP and
254 SNP-set levels for highly heritable phenotypes, respectively. However, both models underestimate the
255 total PVE in polygenic traits and traits with pairwise SNP-by-SNP interactions. Therefore, even though
256 the BANNs framework is still able to correctly prioritize the appropriate SNPs and SNP-sets, in these
257 more complicated settings, we misestimate the approximate posterior means for the network weights and
258 overestimate the variance of the residual training error (Supplementary Notes). Similar observations
259 have been noted when using variational inference [51, 52]. Results from other work also suggest that the
260 sparsity assumption on the SNP-level effects can lead to the underestimation of the PVE [16, 53].

261 **Fine Mapping and Genomic Enrichment in Heterogenous Stock of Mice**

262 We apply the BANNs framework to individual-level genotypes and six quantitative traits in a heteroge-
263 neous stock of mice dataset from the Wellcome Trust Centre for Human Genetics [40]. This data contains
264 approximately 2,000 individuals genotyped at approximately 10,000 SNPs—with specific numbers varying
265 slightly depending on the quality control procedure for each phenotype (Supplementary Notes). For SNP-
266 set annotations, we used the Mouse Genome Informatics database (<http://www.informatics.jax.org>)
267 [54] to map SNPs to the closest neighboring gene(s). Unannotated SNPs located within the same ge-
268 nomic region were labeled as being within the “intergenic region” between two genes. Altogether, a total
269 of 2,616 SNP-sets were analyzed. The six traits that we consider are grouped based on their category
270 and include: body mass index (BMI) and body weight; percentage of CD8+ cells and mean corpuscular
271 hemoglobin (MCH); and high-density and low-density lipoprotein (HDL and LDL, respectively). We
272 choose to analyze these particular traits because their architectures represent a realistic mixture of the
273 simulation scenarios we detailed in the previous section. Specifically, the mice in this study are known to
274 be genetically related and these particular traits have been shown to have various levels of broad-sense
275 heritability with different contributions from both additive and non-additive genetic effects [33].

276 For each trait, we provide a summary table which lists the PIPs for SNPs and SNP-sets after fitting the
277 BANNs model to the individual-level genotypes and phenotype data (Supplementary Tables 11-16). We
278 use Manhattan plots to visually display the variant-level fine mapping results across each of the six traits,

279 where chromosomes are shown in alternating colors for clarity and associated SNPs with PIPs above the
280 median probability model threshold are highlighted (Supplementary Fig. 26). Importantly, many of the
281 candidate genes and intergenic regions selected by the BANNs model have been previously validated by
282 past publications as having some functional relationship with the traits of interest (Table 1). For example,
283 BANNs reports the genes *Btbd9* and *h1b156* as being enriched for the percentage of CD8+ cells in mice
284 (PIP = 0.87 and 0.72, respectively). This same chromosomal region on chromosome 17 was also reported
285 in the original study as having highly significant quantitative trait loci for CD8+ cells (bootstrap posterior
286 probability equal to 1.00) [40]. Similarly, the X chromosome is well known to strongly influence adiposity
287 and metabolism in mice [55]. As expected, in body weight and BMI, our approach identified significant
288 enrichment in this region—headlined by the dystrophin gene *Dmd* in both cases [56]. Finally, we note
289 that including intergenic regions in our analyses allows us to discover trait relevant genomic associations
290 outside the immediate gene annotations provided by the Mouse Genome Informatics database. This
291 proved important for BMI where BANNs reported the region between *Gm22219* and *Mc4r* on chromosome
292 18 as having a relatively high PIP of 0.74. Recently, a large-scale GWA study on individuals from the
293 UK Biobank showed that variants around *MC4R* protect against obesity in humans [57].

294 Overall, the results from this smaller GWA study highlight three key characteristics resulting from the
295 sparse probabilistic assumptions underlying the BANNs framework. First, the variational spike and slab
296 prior placed on the weights of the neural network will select no more than a few variants in a given LD
297 block [46]. This is important since traditional naïve SNP-set methods will often exhibit high false positive
298 rates due to many of these correlated regions along the genome [28]. Second, we see that our findings
299 with BANNs are not biased by the sheer size of SNP-sets. The enrichment of a SNP-set is instead strictly
300 determined by the relative posterior distribution of zero and nonzero SNP-level effect sizes within its
301 annotated genomic window (Supplementary Tables 11-16). In other words, a SNP-set is not guaranteed
302 to have a high inclusion probability just because it contains a SNP with a large nonzero effect; however,
303 BANNs will report a SNP-set as insignificant if the total ratio of non-causal SNPs within the set heavily
304 outweighs the number of causal SNPs that have been annotated for the same region. To this end, in
305 the presence of large SNP-sets, the BANNs framework will favor preserving false discovery rates at the
306 expense of having slightly more false negatives. Lastly, the careful modeling of the SNP-level effect size
307 distributions enhances our ability to conduct multi-scale genomic inference. In this particular study, we
308 show the power to still find trait relevant SNP-sets with variants that are not marginally strong enough
309 to be detected individually, but have notable genetic signal when their weights are aggregated together
310 (again see Table 1 and Supplementary Fig. 26).

311 Analyzing Lipoproteins in the Framingham Heart Study

312 Next, we apply the BANNs framework to two continuous plasma trait measurements — high-density
313 lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol — assayed in 6,950 individuals from
314 the Framingham Heart Study [41] genotyped at 394,174 SNPs genome-wide. Following quality control
315 procedures, we regressed out the top ten principal components of the genotype data from each trait to
316 control for population structure (Supplementary Notes). Next, we used the gene boundaries listed in the
317 NCBI's RefSeq database from the UCSC Genome Browser [42] to define SNP-sets. Similar to the previous
318 sections, unannotated SNPs located within the same genomic region were labeled as being within the
319 “intergenic region” between two genes. This resulted in a total of 18,364 SNP-sets to be analyzed.

320 For each trait, we again fit the BANNs model to the individual-level genotype-phenotype data and
321 used the median probability model threshold as evidence of statistical significance for all weights in the
322 neural network (Supplementary Tables 17-18). In Fig. 4, we show Manhattan plots of the variant-level
323 fine mapping results, where each significant SNP is color coded according to its SNP-set annotation.
324 As an additional validation step, we took the enriched SNP-sets identified by BANNs in each trait
325 and used the gene set enrichment analysis tool Enrichr [58, 59] to identify the categories that they
326 overrepresent in the database of Genotypes and Phenotypes (dbGaP) and the NHGRI-EBI GWAS Catalog

(Supplementary Fig. 27). Similar to our results in the previous section, the BANNs framework identified many SNPs and SNP-sets that have been shown to be associated with cholesterol-related processes in past publications (Table 2). For example, in HDL, BANNs identified an enriched intergenic region between the genes *HERPUD1* and *CETP* (PIP = 1.00) which has been also replicated in multiple GWA studies with multiethnic cohorts [60–63]. The Enrichr analyses were also consistent with published results (Supplementary Fig. 27). For example, the top ten significant enriched categories in the GWAS Catalog (i.e., Bonferroni-correct threshold P -value $< 1 \times 10^{-5}$ or Q -value < 0.05) for HDL-associated SNP-sets selected by the BANNs model are either directly related to lipoproteins and cholesterol (e.g., “Alipoprotein A1 levels”, “HDL cholesterol levels”) or related to metabolic functions (e.g., “Lipid metabolism phenotypes”, “Metabolic syndrome”).

As in the previous analysis, the results from this analysis also highlight insight into complex trait architecture enabled by the variational inference used in the BANNs software. SNP-level results remain consistent with the qualitative assumptions underlying our probabilistic hierarchical model. For instance, previous studies have estimated that rs599839 (chromosome 1, bp: 109822166) and rs4970834 (chromosome 1, bp: 109814880) explain approximately 1% of the phenotypic variation in circulating LDL levels [64]. Since these two SNPs are physically closed to each other and sit in a high LD block ($r^2 \approx 0.63$ with $P < 1 \times 10^{-4}$ [65]), the spike and slab prior in the BANNs framework will maintain the nonzero weight for one and penalize the estimated effect of the other. Indeed, in our analysis, rs4970834 was reported to be associated with LDL (PIP = 0.947), while the effect size of rs599839 was shrunk towards 0 (PIP = 1×10^{-4}). Due to the variational approximations utilized by BANNs (Methods and Supplementary Notes), if two SNPs are in strong LD, the model will tend to select just one of them [26,46].

Replication Study using the UK Biobank

To further validate our results from the Framingham Heart Study, we also independently apply BANNs to analyze HDL and LDL cholesterol traits in ten thousand randomly sampled individuals of European ancestry from the UK Biobank [30]. Here, we filter the imputed genotypes from the UK Biobank to keep only the same 394,174 SNPs that were used in the Framingham Heart Study analyses from the previous section. We then apply BANNs to the individual-level data using the same 18,364 SNP-set annotations based on the NCBI’s RefSeq database from the UCSC Genome Browser [42]. In Supplementary Fig. 28, we show the variant-level Manhattan plots for the independent UK Biobank cohort with significant SNPs color coded according to their SNP-set annotation. Once again, we use the median probability model threshold to determine statistical significance for all weights in the neural network (Supplementary Tables 19-20).

Despite the UK Biobank being a completely independent dataset, we found that BANNs was able to replicate many of the findings that we observed in the Framingham Heart Study analysis (see specially marked rows in Table 2). For example, in HDL, both the variants rs1800775 (PIP = 1.00) and rs17482753 (PIP = 1.00) were replicated. BANNs also identified the corresponding intergenic region between the genes *HERPUD1* and *CETP* as being enriched (PIP = 1.00). In our analysis of LDL, BANNs replicated two out of the four associated SNPs: rs693 within the *APOB* gene, and rs10402271 which falls within the intergenic region between genes *BCAM* and *PVRL2*. There were a few scenarios where a given SNP-set was replicated but the leading SNP in that region differed between the two studies. For instance, while the intergenic region between *LIPG* and *ACAA2* was enriched in both cohorts, the variant rs7240405 was found to be most associated with HDL in the Framingham Heart Study; a different SNP, rs7244811, was identified in the UK Biobank (Fig. 4 and Supplementary Fig. 28). These discrepancies at the variant level are likely due to: (i) the sparsity assumption imposed by BANNs, which lead the model to select one of two variants in high LD; and (ii) ancestry differences among individuals from the two studies likely also generate different LD structures in the same genomic region.

As a final step, we took the enriched SNP-sets identified by BANNs in the UK Biobank and used Enrichr [58, 59] to ensure that we were still obtaining trait relevant results (Supplementary Fig. 29).

375 Indeed, for both HDL and LDL, the most overrepresented categories in dbGaP and the GWAS Catalog
376 (i.e., Bonferroni-correct threshold P -value $< 1 \times 10^{-5}$ or Q -value < 0.05) was consistently the trait of
377 interest—followed by other functionally related gene sets such as “Metabolic syndrome” and “Cholesterol
378 levels”. Overall, demonstrating the ability to statistically replicate results for both fine mapping on the
379 variant-level and enrichment analyses on the SNP-set level in two different independent datasets, only
380 further enhances our confidence about the potential impact of the BANNs framework in GWA studies.

381 Discussion

382 Recently, machine learning approaches have been applied in biomedical genomics for prediction-based
383 tasks, particularly using GWA datasets with the objective of predicting phenotypes [66–69]. However,
384 since the classical idea of variable selection and hypothesis testing is lost within machine learning algo-
385 rithms, they have not been used for association mapping where the goal is to identify significant SNPs or
386 genes underlying complex traits. Here, we present Biologically Annotated Neural Networks (BANNs): a
387 class of feedforward probabilistic models that overcome this central limitation by incorporating partially
388 connected architectures that are guided by predefined SNP-set annotations. This creates a fully inter-
389 pretable framework where the first layer of the neural network encodes SNP-level effects and the neurons
390 within the hidden layer represent the different SNP-set groupings. We frame the BANNs methodology
391 as a Bayesian nonlinear mixed model and use sparse prior distributions to perform variable selection on
392 the network weights. By implementing a novel and integrative variational inference algorithm, we are
393 able to derive posterior inclusion probabilities (PIPs) which allows researchers to carry out SNP-level
394 fine-mapping and SNP-set enrichment analyses, simultaneously. While we focus on genomic motivations
395 in this study, the concept of partially connected neural networks may extend to any scientific application
396 where annotations can help guide the groupings of variables.

397 Through extensive simulation studies, we demonstrate the utility of the BANNs framework on individual-
398 level data (Fig. 1) and GWA summary statistics (Supplementary Fig. 1). Here, we showed that both
399 implementations consistently outperform commonly used SNP-level fine-mapping methods and state-of-
400 the-art SNP-set enrichment methods in a wide range of genetic architectures (Figs. 2-3, Supplementary
401 Figs. 2-23, and Supplementary Tables 1-8). This advantage was most clear when the broad-sense her-
402 itability of the complex traits included pairwise genetic interactions. In two real GWA datasets, we
403 demonstrated the ability of BANNs to prioritize trait relevant SNPs and SNP-sets that have been identi-
404 fied by previous publications and functional validation studies (Fig. 4, Supplementary Figs. 26-27, Tables
405 1-2, and Supplementary Tables 11-18). Lastly, using a third real dataset, we then showed the ability of
406 BANNs to statistically replicate these findings in an independent cohort (Supplementary Figs. 28-29 and
407 Supplementary Tables 19-20).

408 The current implementation of the BANNs framework offers many directions for future development
409 and applications. Perhaps the most obvious limitation is that ill-annotated SNP-sets can bias the in-
410 terpretation of results and lead to misplaced scientific conclusions (i.e., might cause us to highlight the
411 “wrong” gene [70, 71]). This is a common issue in most enrichment methods [28]; however, similar to
412 other hierarchical methods like RSS [26], BANNs is likely to rank SNP-set enrichments that are driven by
413 just a single SNP as less reliable than enrichments driven by multiple SNPs with nonzero effects. Another
414 current limitation for the BANNs model comes from the fact that it uses variational inference to estimate
415 its parameters. While the current implementation is scalable for large datasets (Supplementary Tables
416 9 and 10), we showed that the variational algorithm can lead to underestimated approximations of the
417 PVE (Supplementary Figs. 24 and 25) and will occasionally miss causal SNPs if they are in high LD with
418 other non-causal SNPs in the dataset. For example, in the application to the Framingham Heart Study,
419 BANNs estimates the PVE for HDL and LDL to be 0.11 and 0.04, respectively. Similarly, in the UK
420 Biobank replication study, BANNs estimates the PVE for HDL and LDL to be 0.12 and 0.06, respectively.
421 In general, these values are lower than what is typically reported in the literature for these complex phe-

422 notypes (PVE $\geq 27\%$ for HDL and PVE $\geq 21\%$ for LDL, respectively) [72]. Exploring alternative ways
423 to carry out approximate Bayesian inference is something to consider for future work [73].

424 There are several other potential extensions for the BANNs framework. First, in the current study,
425 we only consider a single hidden layer based on the annotations of gene boundaries and intergenic region
426 between genes. One natural direction for future work would be to take more of a deep learning
427 approach by including additional hidden layers to the neural network where genes are grouped based
428 on signaling pathways or other functional ontologies. This would involve integrating information from
429 curated databases such as MSigDB [74, 75]. Second, the current BANNs model only takes in genetic
430 information and ignores other sources of variation (e.g., population structure). In the future, we would
431 like to expand the framework to also take in covariates as fixed effects in the model. Third, we have
432 only focused on analyzing one phenotype at a time in this study. However, many previous studies
433 have extensively shown that modeling multiple phenotypes can often dramatically increase power [76].
434 Therefore, it would be interesting to extend the BANNs framework to take advantage of phenotype
435 correlations to identify pleiotropic epistatic effects. Modeling strategies based on the multivariate linear
436 mixed model (mvLMM) [77] and matrix variate Gaussian process (mvGP) [78] could be helpful here.

437 As a final avenue for future work, we only focused on applying BANNs to quantitative traits. For
438 studies interested in extending this approach to binary traits (i.e., case-control studies), one might be
439 tempted to simply place a sigmoid or logistic link function on the penultimate layer of the neural network.
440 Indeed, this would allow the BANNs framework to be expressed as a (nonlinear) logistic mixed model
441 which is an approach that has been well-established in the statistics literature [79–81]. Unfortunately, it
442 is not straightforward to define broad-sense heritability under the traditional logistic mixed model and
443 controlling for additional confounders that can occur within case-control studies (e.g., ascertainment)
444 can be difficult. As one alternative, we could implement a penalized quasi-likelihood approach [82] which
445 has been shown to enable effective heritability estimation and differential analyses using the generalized
446 linear mixed model framework. As a second alternative, the liability threshold mixed model avoids issues
447 by assuming that binary traits can be modeled via continuous latent liability scores [83–85]. Therefore,
448 a potentially effective way to extend BANNs to case-control studies would be to develop a two-step
449 algorithmic procedure where: in the first step, we find the posterior mean of the liability scores be
450 using existing software packages and then, in the second step, treat those empirical liability estimates
451 as observed traits in the neural network. Regardless of the modeling strategy, new algorithms are likely
452 needed to maximize the appropriateness of BANNs for non-continuous phenotypes.

453 URLs

454 Biologically annotated neural networks (BANNs) software, <https://github.com/lcrawlab/BANNs>; UK
455 Biobank, <https://www.ukbiobank.ac.uk>; Database of Genotypes and Phenotypes (dbGaP), <https://www.ncbi.nlm.nih.gov/gap>;
456 Framingham Heart Study (FHS), <https://www.ncbi.nlm.nih.gov/gap>;
457 NHGRI-EBI GWAS Catalog, <https://www.ebi.ac.uk/gwas/>; UCSC Genome Browser, <https://genome.ucsc.edu/index.html>;
458 Enrichr software, <http://amp.pharm.mssm.edu/Enrichr/>; Wellcome
459 Trust Centre for Human Genetics, <http://mtweb.cs.ucl.ac.uk/mus/www/mouse/index.shtml>;
460 Mouse Genome Informatics database, <http://www.informatics.jax.org>; Causal Variants Identification in
461 Associated Regions (CAVIAR) software, <http://genetics.cs.ucla.edu/caviar/>;
462 Efficient variable selection using summary data from GWA studies (FINEMAP) software, <http://www.christianbenner.com>;
463 Generalized Berk-Jones (GBJ) test for set-based inference software, <https://cran.r-project.org/web/packages/GBJ/>;
464 Gene Set Enrichment Analysis (GSEA) software, <https://www.nr.no/en/projects/software-genomics>;
465 SNP-set (Sequence) Kernel Association Test (SKAT) software, <https://www.hsph.harvard.edu/skat>;
466 Sum of Single Effects (SuSiE) variable selection software, <https://github.com/stephenslab/susier>;
467 Multi-marker Analysis of GenoMic Annotation (MAGMA) software, <https://ctg.cncr.nl/software/magma>;
468 Precise, Efficient Gene Association Score Using SNPs (PE-

469 GASUS) software, <https://github.com/ramachandran-lab/PEGASUS>; and Regression with Summary
470 Statistics (RSS) enrichment software, <https://github.com/stephenslab/rss>.

471 Acknowledgements

472 This research was conducted in part using computational resources and services at the Center for Com-
473 putation and Visualization at Brown University. This research was conducted using the UK Biobank
474 Resource under Application Number 22419. This research was also conducted in part using data and
475 resources from the Framingham Heart Study of the NHLBI and Boston University School of Medicine,
476 which was partially supported by the NHLBI Framingham Heart Study (Contract No. N01-HC-25195)
477 and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). We thank
478 all participants and staff from the Framingham Heart Study.

479 Funding

480 This research was supported in part by US National Institutes of Health (NIH) grant R01 GM118652,
481 and National Science Foundation (NSF) CAREER award DBI-1452622 to S. Ramachandran. This re-
482 search was also partly supported by grants P20GM109035 (COBRE Center for Computational Biology
483 of Human Disease; PI Rand) and P20GM103645 (COBRE Center for Central Nervous; PI Sanes) from
484 the NIH NIGMS, 2U10CA180794-06 from the NIH NCI and the Dana Farber Cancer Institute (PIs Gray
485 and Gatsonis), as well as by an Alfred P. Sloan Research Fellowship (No. FG-2019-11622) awarded to
486 L. Crawford. G. Darnell was supported by NSF Grant No. DMS-1439786 while in residence at the
487 Institute for Computational and Experimental Research in Mathematics (ICERM) in Providence, RI.
488 X. Zhou was supported by the NIH grant R01HG009124 and the NSF Grant DMS1712933. Any opin-
489 ions, findings, and conclusions or recommendations expressed in this material are those of the author(s)
490 and do not necessarily reflect the views of any of the funders.

491 Author Contributions

492 LC conceived the methods. PD and WC developed the software and carried out the analyses. All authors
493 wrote and reviewed the manuscript.

494 Competing Interests

495 The authors declare no competing interests.

496 Methods

497 Annotations

498 We used the NCBI’s Reference Sequence (RefSeq) database in the UCSC Genome Browser [42] to annotate
 499 SNPs with appropriate SNP-sets. In the main text, we consider a SNP being “inside” a gene using the
 500 UCSC gene boundary definitions directly. Genes with only one SNP within their boundary were excluded
 501 from either analysis. Unannotated SNPs located within the same genomic region are labeled as being
 502 within the “intergenic region” between two genes. Altogether, with annotated genes and labeled intergenic
 503 regions, a total of 28,644 SNP-sets were analyzed.

504 Biologically Annotated Neural Networks

505 Consider a genome-wide association (GWA) study with N individuals. We have an N -dimensional vector
 506 of quantitative traits \mathbf{y} , an $N \times J$ matrix of genotypes \mathbf{X} , with J denoting the number of single nucleotide
 507 polymorphisms (SNPs) encoded as $\{0, 1, 2\}$ copies of a reference allele at each locus, and a list of G -
 508 predefined SNP-sets $\{\mathcal{S}_1, \dots, \mathcal{S}_G\}$ (Fig. 1a). Let each SNP-set g represent a known collection of annotated
 509 SNPs $j \in \mathcal{S}_g$ with cardinality $|\mathcal{S}_g|$. For example, \mathcal{S}_g may include SNPs within the regulatory region of a
 510 gene. The BANNs framework assumes a partially connected Bayesian neural network architecture based
 511 on SNP-set annotations to learn the phenotype of interest for each observation in the data (Fig. 1b).
 512 Formally, we specify this network as a nonlinear regression model (Fig. 1c)

$$513 \quad \mathbf{y} = \sum_{g=1}^G h(\mathbf{X}_g \boldsymbol{\theta}_g + \mathbf{1}b_g^{(1)})w_g + \mathbf{1}b^{(2)}, \quad (1)$$

514 where $\mathbf{X}_g = [\mathbf{x}_1, \dots, \mathbf{x}_{|\mathcal{S}_g|}]$ is the subset of SNPs annotated for SNP-set g ; $\boldsymbol{\theta}_g = (\theta_1, \dots, \theta_{|\mathcal{S}_g|})$ are the
 515 corresponding inner layer weights; $h(\bullet)$ denotes the nonlinear activations defined for neurons in the
 516 hidden layer; $\mathbf{w} = (w_1, \dots, w_G)$ are the weights for the G -predefined SNP-sets in the hidden layer;
 517 $\mathbf{b}^{(1)} = (b_1^{(1)}, \dots, b_G^{(1)})$ and $b^{(2)}$ are deterministic biases that are produced during the network training
 518 phase in the input and hidden layers, respectively; and $\mathbf{1}$ is an N -dimensional vector of ones. For
 519 convenience, we assume that the genotype matrix (column-wise) and trait of interest have been mean-
 520 centered and standardized. In the main text, $h(\bullet)$ is defined as a Leaky rectified linear unit (Leaky ReLU)
 521 activation function [86], where $h(\mathbf{x}) = \mathbf{x}$ if $\mathbf{x} > \mathbf{0}$ and $0.01\mathbf{x}$ otherwise. Note that Eq. (1) can be seen as
 522 a nonlinear take on classic integrative and structural regression models [22, 26, 87–90] frequently used in
 523 GWA analyses.

524 Part of the key methodological innovation in the BANNs framework is to treat the weights of the input
 525 (θ_j) and hidden layers (w_g) as random variables. This enables us to perform interpretable association
 526 mapping on both SNPs and SNP-sets, simultaneously. For the weights on the input layer, our goal is to
 527 approximate a wide range of possible SNP-level effect size distributions underlying complex traits. To
 528 this end, we assume that SNP-level effects follow a K -mixture of normal distributions [10, 43–45]

$$529 \quad \theta_j \sim \sum_{k=1}^K \pi_{\theta k} \mathcal{N}(0, \sigma_{\theta k}^2), \quad \log(\pi_{\theta k}) \sim \mathcal{U}(-\log(J), \log(1)), \quad \sigma_{\theta k}^2 \sim \text{Inv-Gamma}(u_\theta, v_\theta) \quad (2)$$

530 where $\boldsymbol{\pi}_\theta = (\pi_{\theta 1}, \dots, \pi_{\theta K})$ represents the marginal (unconditional) probability that a randomly selected
 531 SNP belongs to the k -th mixture component (with $\sum_k \pi_{\theta k} = 1$). The prior in Eq. (2) models distinct
 532 types of nonzero SNP-level effects through the K different variance components $\boldsymbol{\sigma}_\theta^2 = (\sigma_{\theta 1}^2, \dots, \sigma_{\theta K}^2)$.
 533 We allow sequential fractions of SNPs ($\pi_{\theta 1}, \dots, \pi_{\theta K}$) to correspond to distinctly smaller effects ($\sigma_{\theta 1}^2 >$
 534 $\dots > \sigma_{\theta K}^2 = 0$) [44]. Intuitively, specifying a larger K allows the neural network to learn general SNP
 535 effect size distributions spanning over a diverse class of trait architectures. For results in the main text,

we fix $K = 3$ for computational reasons. This corresponds to the hypothesis that SNPs can have large, moderate, and small effects on phenotypic variation [28]. We place a uniform prior on $\log \pi_{\theta k}$ to coincide with the observation that the number of SNPs in each of these categories can vary greatly depending on how heritability is distributed across the genome [16, 53]. Similarly, because we do not know the magnitude for SNP effects in each category, we place relatively diffuse inverse-gamma priors on each of the variance components to allow the posterior of $\boldsymbol{\theta}$ to be primarily driven by information contained within the genotype data at hand (see Supplementary Notes).

For inference on the hidden layer, we assume that enriched SNP-sets contain at least one SNP with a nonzero effect. This criterion is formulated by placing a spike and slab prior on the hidden layer weights

$$w_g \sim \pi_w \mathcal{N}(0, \sigma_w^2) + (1 - \pi_w) \delta_0, \quad \log(\pi_w) \sim \mathcal{U}(-\log(G), \log(1)), \quad \sigma_w^2 \sim \text{Inv-Gamma}(u_w, v_w) \quad (3)$$

where, in addition to previous notation, δ_0 is a point mass at zero, and π_w denotes the total proportion of annotated SNP-sets that are enriched for the trait of interest. Given the structural form of the joint likelihood in Eq. (1), the magnitude of association for a SNP-set will be directly influenced by the effect size distribution of the SNPs it contains.

We use a scalable variational Bayesian algorithm to estimate all model parameters (Supplemental Note). As the BANNs network is trained, the posterior mean for the weights of non-associated SNP and SNP-sets are set to zero, leaving only a sparse subset of trait relevant neurons to predict the phenotype. We use posterior inclusion probabilities (PIPs) as a general summaries of evidence for SNPs and SNP-sets being associated with phenotypic variation. Here, we respectively define

$$\gamma_{\theta_j} = \Pr[\theta_j \neq 0 | \mathbf{y}, \mathbf{X}], \quad \gamma_{w_g} = \Pr[w_g \neq 0 | \mathbf{y}, \mathbf{X}, \boldsymbol{\theta}_g] \quad (4)$$

where, again for the latter, the enrichment of SNP-sets is conditioned on the association of individual SNPs. The goal of the sparse shrinkage priors in Eqs. (2)-(3) is similar to that of regularization via “dropout” in the machine and deep learning literature where the connections between units in a neural network are dropped according to a penalized loss function [91]. The Bayesian formulation in the BANNs framework makes network sparsity more targeted for GWA applications through contextually motivated prior distributions. Moreover, posterior inference on $\boldsymbol{\gamma}_\theta = (\gamma_{\theta 1}, \dots, \gamma_{\theta J})$ and $\boldsymbol{\gamma}_w = (\gamma_{w 1}, \dots, \gamma_{w G})$ detail the degree to which nonzero weights occur.

Posterior Computation with Variational Inference

We combine the likelihood in Eq. (1) and the prior distributions in Eqs. (2)-(4) to perform Bayesian inference. With the size of high-throughput GWA datasets, it is less feasible to implement traditional Markov Chain Monte Carlo (MCMC) algorithms due to the large dimensionality of the parameter space. For scalable model fitting we modify a previously established variational expectation-maximization (EM) algorithm for integrative network parameter estimation [46]. The overall goal of variational inference is to approximate the true posterior distribution for network parameters with a “best match” distribution from an approximating family [51]. The EM algorithm we use aims to minimize the Kullback-Leibler divergence between the exact and approximate posterior distributions.

To compute the variational approximations, we make the mean-field assumption that the true posterior can be “fully-factorized” [92]. The algorithm then follows three general steps. First, we assign exchangeable uniform hyper-priors over a grid of values on the log-scale for $\boldsymbol{\pi}_\theta$ and π_w [46]. Next, we iterate through each combination of hyper-parameter values and compute variational updates for the other parameters using co-ordinate ascent. Lastly, we empirically compute (approximate) posterior values for the network connections ($\boldsymbol{\theta}, \mathbf{w}$) and their corresponding inclusion probabilities ($\boldsymbol{\gamma}_\theta, \boldsymbol{\gamma}_w$) by marginalizing over the different hyper-parameter combinations. This final step can be viewed as an analogy to Bayesian model averaging where marginal distributions are estimated via a weighted average of conditional distributions multiplied by importance sampling weights [93]. Throughout the model fitting procedure, we

581 assess two different lower bounds for the input and hidden layers to check convergence of the algorithm.
582 The first lower bound is maximized with respect to the SNP-level effects on the observed trait of interest;
583 while, the second lower bound on the SNP-set level enrichments. The software code iterates between the
584 “inner” lower bound and the “outer” lower bound each step of the algorithm until convergence. Detailed
585 steps in the variational EM algorithm and explicit co-ordinate ascent updates for network parameters are
586 given in Supplementary Notes.

587 Parameters in the variational EM algorithm are initialized by taking a random draws from their
588 assumed prior distributions. Iterations in the algorithm are terminated when either one of two stopping
589 criteria are met: (i) the difference between the lower bound of two consecutive updates are within some
590 small range (specified by argument ϵ), or (ii) a maximum number of iterations is reached. For the
591 simulations and real data analyses ran in this paper, we set $\epsilon = 1 \times 10^{-4}$ for the first criterion and used
592 a maximum of 10,000 iterations for the second.

593 Extensions to Summary Statistics

594 The BANNs framework also models summary statistics in the event that individual-level genotype and
595 phenotype data are not accessible. Here, the software takes alternative inputs: GWA marginal effect size
596 estimates $\hat{\boldsymbol{\theta}}$, and an empirical linkage disequilibrium (LD) matrix \mathbf{R} . In the main text, we refer to this
597 version of the method as the BANN-SS model. We assume that GWA summary statistics are derived
598 from the following generative linear model for complex traits

$$599 \quad \mathbf{y} = \mathbf{X}\boldsymbol{\theta} + \mathbf{e}, \quad \mathbf{e} \sim \mathcal{N}(\mathbf{0}, \tau^2\mathbf{I}) \quad (5)$$

600 where \mathbf{e} is a normally distributed error term with mean zero and scaled variance τ^2 , and \mathbf{I} is an $N \times N$
601 identity matrix. For every j -th SNP, the ordinary least squares (OLS) estimates are based on the
602 generative model $\hat{\theta}_j = (\mathbf{x}_j^T \mathbf{x}_j)^{-1} \mathbf{x}_j^T \mathbf{y}$, where \mathbf{x}_j is the j -th column of the genotype matrix \mathbf{X} and $\hat{\theta}_j$ is
603 the j -th entry of the vector $\hat{\boldsymbol{\theta}}$. We assume the LD matrix \mathbf{R} is empirically estimated from external
604 data (e.g., directly from GWA study data, or using an LD map from a population with similar genomic
605 ancestry to that of the samples analyzed in the GWA study). The BANN-SS model treats the observed
606 OLS estimates and LD matrix as “proxies” for the unobserved phenotype and genotypes, respectively.
607 Specifically, for large sample size N , we consider the asymptotic relationship between the expectation of
608 the observed GWA effect size estimates $\hat{\boldsymbol{\theta}}$ and the true coefficient values $\boldsymbol{\theta}$ is [28, 38, 44, 94]

$$609 \quad \mathbb{E}[\hat{\boldsymbol{\theta}}_j] = \sum_{j'=1}^J r(\mathbf{x}_j, \mathbf{x}_{j'}) \theta_{j'} \quad (6)$$

610 where $r(\mathbf{x}_j, \mathbf{x}_{j'})$ denotes the correlation coefficient between SNPs \mathbf{x}_j and $\mathbf{x}_{j'}$. The above resembles a high-
611 dimensional regression model with the OLS effect sizes $\hat{\boldsymbol{\theta}}$ as the response variables, the LD matrix \mathbf{R} as the
612 design matrix, and the true coefficients $\boldsymbol{\theta}$ being the SNP-level effects that generated the phenotype. With
613 this relationship in mind, the BANN-SS framework implements the following sparse nonlinear regression
614 for inferring multi-scale genomic effects from summary statistics (Supplementary Fig. 1)

$$615 \quad \hat{\boldsymbol{\theta}} = \sum_{g=1}^G h(\mathbf{R}_g \boldsymbol{\theta}_g + \mathbf{1}b_g^{(1)})w_g + \mathbf{1}b^{(2)}, \quad (7)$$

616 where, in addition to previous notation, \mathbf{R}_g is the subset of the LD matrix involving all SNPs annotated
617 for the g -th SNP-set. Using the rewritten joint likelihood in Eq. (7), posterior Bayesian inference for
618 the parameters in the BANN-SS model directly mirrors the procedure used when we have access to
619 individual-level data (i.e., as described previously in Eqs. (2)-(4); Supplementary Note). Again, we use
620 PIPs $\gamma_{\boldsymbol{\theta}}$ and γ_w to summarize whether the true SNP-level effects and aggregated effects on the SNP-set
621 level are statistically associated with the trait of interest.

622 Simulation Studies

623 We used a simulation scheme to generate quantitative traits under multiple genetic architectures using
624 real genotype data on chromosome 1 from individuals of European ancestry in the UK Biobank. First,
625 we randomly select a subset of associated SNP-sets (i.e., collections of genomic regions) and assume that
626 complex traits are generated via the linear mixed model

$$627 \quad \mathbf{y} = \mathbf{Z}\boldsymbol{\mu} + \sum_{c \in \mathcal{C}} \mathbf{x}_c \theta_c + \mathbf{W}\boldsymbol{\varphi} + \boldsymbol{\varepsilon}, \quad \boldsymbol{\varepsilon} \sim \mathcal{N}(\mathbf{0}, \tau^2 \mathbf{I}), \quad (8)$$

628 where \mathbf{y} is an N -dimensional vector containing all the phenotypes; \mathcal{C} represents the set of causal SNPs
629 contained within the associated SNP-sets; \mathbf{x}_c is the genotype for the c -th causal SNP encoded as 0,
630 1, or 2 copies of a reference allele; θ_c is the additive effect size for the c -th SNP; \mathbf{W} is an $N \times E$
631 matrix which holds all pairwise interactions between the causal SNPs with corresponding effects $\boldsymbol{\varphi}$;
632 \mathbf{Z} is an $N \times M$ matrix of covariates representing additional population structure (e.g., the top ten
633 genotype principal components from the genotype matrix) with corresponding fixed effects $\boldsymbol{\mu}$; and $\boldsymbol{\varepsilon}$ is
634 an N -dimensional vector of environmental noise. The phenotypic variance is assumed $\mathbb{V}[\mathbf{y}] = 1$. The
635 additive and interaction effect sizes of SNPs in associated SNP-sets are randomly drawn from standard
636 normal distributions and then rescaled so they explain a fixed proportion of the broad-sense heritability
637 $\mathbb{V}[\sum \mathbf{x}_c \theta_c] + \mathbb{V}[\mathbf{W}\boldsymbol{\varphi}] = H^2$. Together with the centered and scaled genetic random effects, we get a total
638 phenotypic variance explained for each trait $\text{PVE} = H^2 + \mathbb{V}[\mathbf{Z}\boldsymbol{\mu}]$. Lastly the environment noise is rescaled
639 such that $\mathbb{V}[\boldsymbol{\varepsilon}] = 1 - \text{PVE}$. The full genotype matrix and phenotypic vector are given to the BANNs
640 model and all other competing methods that require individual-level data. For the BANN-SS model and
641 other competing methods that take GWA summary statistics, we fit a single-SNP univariate linear model
642 via ordinary least squares (OLS) to obtain: coefficient estimates $\hat{\theta}_j = (\mathbf{x}_j^\top \mathbf{x}_j)^{-1} \mathbf{x}_j^\top \mathbf{y}$, standard errors
643 $\hat{s}_j^2 = J^{-1}(\mathbf{y} - \mathbf{x}_j \hat{\theta}_j)^\top (\mathbf{y} - \mathbf{x}_j \hat{\theta}_j) / \mathbf{x}_j^\top \mathbf{x}_j$, and P -values for all SNPs in the data. We also obtain an empirical
644 estimate of the linkage disequilibrium (LD) matrix for these methods \mathbf{R} , which we compute directly from
645 the full genotype matrix. Given different model parameters, we simulate data mirroring a wide range of
646 genetic architectures (Supplementary Notes).

647 Data and Software Availability

648 Source code (with versions in both R and Python 3) and tutorials for implementing biologically annotated
649 neural networks (BANNs) is publicly available online at <https://github.com/lcrawlab/BANNs>. All
650 software for competing methods were fit using the default settings, unless otherwise stated in the main
651 text. Links to competing methods, WTCHG mice data, and other relevant sources are also provided (See
652 URLs). Data from the UK Biobank Resource [30] (<https://www.ukbiobank.ac.uk>) was made available
653 under Application Number 22419. The FHS genotype and phenotype data is available in dbGaP [41]
654 (<https://www.ncbi.nlm.nih.gov/gap>) with accession number phs000007.

655

Figures and Tables




Figure 1. Biologically annotated neural networks (BANNs) allow for efficient multi-scale genotype-phenotype analyses in a unified probabilistic framework by leveraging the hierarchical nature of enrichment studies to define network architecture. (a) The BANNs framework requires an $N \times J$ matrix of individual-level genotypes $\mathbf{X} = [x_1, \dots, x_j]$, an N -dimensional phenotypic vector \mathbf{y} , and a list of G -predefined SNP-sets $\{S_1, \dots, S_G\}$. In this work, SNP-sets are defined as genes and intergenic regions (between genes) given by the NCBI’s Reference Sequence (RefSeq) database in the UCSC Genome Browser [42]. (b) A partially connected Bayesian neural network is constructed based on the annotated SNP groups. In the first hidden layer, only SNPs within the boundary of a gene are connected to the same node. Similarly, SNPs within the same intergenic region between genes are connected to the same node. Completing this specification for all SNPs gives the hidden layer the natural interpretation of being the “SNP-set” layer. (c) The hierarchical nature of the network is represented as nonlinear mixed model. The corresponding weights in both the SNP (θ) and SNP-set (w) layers are treated as random variables with biologically motivated sparse prior distributions. Posterior inclusion probabilities (PIPs) γ_θ and γ_w summarize associations at the SNP and SNP-set level, respectively. The BANNs framework uses variational inference for efficient network training and incorporates nonlinear processing between network layers for accurate estimation of phenotypic variance explained (PVE).




Figure 2. Receiver operating characteristic (ROC) curves comparing the performance of the BANNs (red) and BANN-SS (black) models with competing SNP and SNP-set mapping approaches in simulations. Here, quantitative traits are simulated to have broad-sense heritability of $H^2 = 0.6$ with only contributions from additive effects set (i.e., $\rho = 1$). We show power versus false positive rate for two different trait architectures: **(a, b)** sparse where only 1% of SNP-sets are enriched for the trait; and **(c, d)** polygenic where 10% of SNP-sets are enriched. We set the number of causal SNPs with nonzero effects to be 0.125% and 3% of all SNPs located within the enriched SNP-sets, respectively. To derive results, the full genotype matrix and phenotypic vector are given to the BANNs model and all competing methods that require individual-level data. For the BANN-SS model and other competing methods that take GWA summary statistics, we compute standard GWA SNP-level effect sizes and P -values (estimated using ordinary least squares). **(a, c)** Competing SNP-level mapping approaches include: CAVIAR [38], SuSiE [39], and FINEMAP [37]. The software for SuSiE requires an input ℓ which fixes the maximum number of causal SNPs in the model. We display results when this input number is high ($\ell = 3000$) and when this input number is low ($\ell = 10$). **(b, d)** Competing SNP-set mapping approaches include: RSS [26], PEGASUS [25], GBJ [27], SKAT [21], GSEA [36], and MAGMA [23]. Note that the upper limit of the x-axis has been truncated at 0.1. All results are based on 100 replicates (see Supplementary Note, Section 8).




Figure 3. Scatter plots comparing how the integrative neural network training procedure enables the ability to identify associated SNPs and enriched SNP-sets in simulations. Quantitative traits are simulated to have broad-sense heritability of $H^2 = 0.6$ with only contributions from additive effects set (i.e., $\rho = 1$). We consider two different trait architectures: **(a, b)** sparse where only 1% of SNP-sets are enriched for the trait; and **(c, d)** polygenic where 10% of SNP-sets are enriched. We set the number of causal SNPs with nonzero effects to be 0.125% and 3% of all SNPs located within the enriched SNP-sets, respectively. Results are shown comparing the posterior inclusion probabilities (PIPs) derived by the BANNs model on the x-axis and **(a, c)** SuSiE [39] and **(b, d)** RSS [26] on the y-axis, respectively. Here, SuSiE is fit while assuming a high maximum number of causal SNPs ($\ell = 3000$). The blue horizontal and vertical dashed lines are marked at the “median probability criterion” (i.e., PIPs for SNPs and SNP-sets greater than 0.5) [47]. True positive causal variants used to generate the synthetic phenotypes are colored in red, while non-causal variants are given in grey. SNPs and SNP-sets in the top right quadrant are selected by both approaches; while, elements in the bottom right and top left quadrants are uniquely identified by BANNs and SuSiE/RSS, respectively. Each plot combines results from 100 simulated replicates (see Supplementary Notes).

Trait	SNP-Set	Chr	PIP (γ_θ)	Rank	Top SNP	PIP (γ_w)	Biological Relevance to Trait	Ref(s)
BMI	<i>Dmd</i>	X	0.900	1	rs3090667	0.600	Dystrophin loss has integrative effects on metabolic function	[56]
	<i>Mir466q-Slc2a2</i>	3	0.816	3	rs6269713	0.477	Encodes <i>GLUT2</i> and shown to vary with BMI in humans	[95]
	<i>Gm22219-Mc4r</i>	18	0.740	5	rs3696955	0.039	<i>MC4R</i> variants protect against obesity in humans	[57]
CD8+	<i>Gm46177-Gm30088</i>	1	0.968	1	mhcCD8a3	1.000	Intergenic region containing lupus related QTL that are linked to CD8+ T cell differentiation	[96–98]
	<i>Btbd9</i>	17	0.866	7	CEL-17_31069801	1.000	Contains SNPs associated with restless leg syndrome and is positioned within a QTL associated with iron concentration	[99, 100]
	<i>h1b156</i>	17	0.720	8	CEL-17_31069801	1.000	Heart, lung, and blood functionally related gene	[54]
HDL	<i>Pphc2</i>	4	0.976	3	rs3724711	1.000	Involved in cholesterol metabolic processes	[101]
	<i>Ctnna2</i>	6	0.886	8	rs3710419	1.000	Shown to be associated with the abnormality of cholesterol metabolism in different GWA studies	[102]
	<i>h1b156</i>	17	0.589	8	CEL-17_31069801	1.000	Heart, lung, and blood functionally related gene	[54]
LDL	<i>Btbd9</i>	17	0.983	1	CEL-17_31069801	1.000	Mutations in this gene have been linked to Bardet-Biedl syndrome, for which truncal obesity is a cardinal symptom	[103, 104]
	<i>Pphc2</i>	4	0.941	3	rs3724711	1.000	Involved in cholesterol metabolic processes	[101]
	<i>Syt14</i>	1	0.852	7	rs3654706	0.001	Also known as the RIKEN gene and involved in processes dealing with lipid binding	[105–107]
MCH	<i>Btbd9</i>	17	0.905	2	CEL-17_31069801	1.000	Contains SNPs associated with restless leg syndrome and is positioned within a QTL associated with iron concentration	[99, 100]
	<i>Picalm</i>	7	0.648	8	rs3704554	0.070	Mutations in this gene are responsible for the hematopoietic and iron metabolism abnormalities in mice	[109]
	<i>Ebf1</i>	11	0.500	10	rs3693846	0.009	Knockout experiments with this gene have been linked to B-cell deficiency and other hematopoietic system changes in mice	[110]
Weight	<i>Wdpcp</i>	11	0.969	1	rs13481023	1.000	Mutations in this gene have been linked to Bardet-Biedl syndrome, for which truncal obesity is a cardinal symptom	[103, 104]
	<i>Chrm2</i>	6	0.882	3	rs3676478	0.012	The genotypic variance of this gene has been shown to be predictive of longitudinal BMI and obesity status	[111, 112]
	<i>Csmd1</i>	8	0.759	5	rs3709567	0.001	Knockout experiments with this gene have been linked to weight gain in mice	[113]

Table 1. Notable enriched SNP-sets after applying the BANNs framework to six quantitative traits in heterogenous stock of mice from the Wellcome Trust Centre for Human Genetics. [40]. The traits include: body mass index (BMI), percentage of CD8+ cells, high-density lipoprotein (HDL), low-density lipoprotein (LDL), mean corpuscular hemoglobin (MCH), and body weight. Here, SNP-set annotations are based on gene boundaries defined by the Mouse Genome Informatics database (see URLs). Unannotated SNPs located within the same genomic region were labeled as being within the “intergenic region” between two genes. These regions are labeled as *Gene1-Gene2* in the table. Posterior inclusion probabilities (PIP) for the input and hidden layer weights are derived by fitting the BANNs model on individual-level data. A SNP-set is considered enriched if it has a PIP $\gamma_w \geq 0.5$ (i.e., the “median probability model” threshold [47]). We also report the “top” associated SNP within each region and its corresponding PIP γ_θ . The reference column details literature sources that have previously suggested some level of association between the each genomic region and the traits of interest. See Supplementary Tables 11-16 for the complete list of SNP and SNP-set level results. *: Multiple SNP-sets were tied for this ranking.




Figure 4. Manhattan plot of variant-level fine mapping results for high-density and low-density lipoprotein (HDL and LDL, respectively) traits in the Framingham Heart Study [41]. Posterior inclusion probabilities (PIP) for the neural network weights are derived from the BANNs model fit on individual-level data and are plotted for each SNP against their genomic positions. Chromosomes are shown in alternating colors for clarity. The black dashed line is marked at 0.5 and represents the “median probability model” threshold [47]. SNPs with PIPs above that threshold are color coded based on their SNP-set annotation. Here, SNP-set annotations are based on gene boundaries defined by the NCBI’s RefSeq database in the UCSC Genome Browser [42]. Unannotated SNPs located within the same genomic region were labeled as being within the “intergenic region” between two genes. These regions are labeled as *Gene1-Gene2* in the legend. Gene set enrichment analyses for these SNP-sets can be found in Supplementary Figure 27. Results for a replication study using ten thousand randomly sampled individuals of European ancestry from the UK Biobank [30] can be found in Supplementary Figures 28 and 29.

Trait	SNP-Set	Chr	PIP (γ_w)	Rank	Top SNP	PIP (γ_θ)	Biological Relevance to Trait	Ref(s)
HDL	<i>HERPUD1-CETP</i> ♣	16	0.999	1*	rs7240405♣	0.923	Previously found to be associated with HDL in multiple multiethnic GWA studies	[60–63]
	<i>ST18-FAM150A</i>	8	0.999	1*	rs6990075	1.000	Suppression of mouse ortholog has been shown facilitate high glucose-induced cell death	[114]
	<i>TCEA3</i>	1	0.989	2	rs1767141	0.868	Found to be commonly associated with total cholesterol measurement across multiple cohorts	[115]
LDL	<i>CELSR2</i>	1	0.989	1	rs4970834	0.948	Member of the cadherin superfamily and commonly found to be associated with LDL across multiple multiethnic cohorts	[116–118]
	<i>BCAM-PVRL2</i> ♣	19	0.987	2	rs10402271♣	0.998	<i>BCAM</i> encodes a Lutheran blood group glycoprotein, while <i>PVRL2</i> is a cholesterol-responsive gene. Both have been linked to LDL response	[119–121]
	<i>APOB</i> ♣	2	0.976	3	rs693♣	0.999	This gene produces the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), and is the ligand for the LDL receptor	[119, 122, 123]

Table 2. Top three enriched SNP-sets after applying the BANNs framework to high-density and low-density lipoprotein (HDL and LDL, respectively) traits in the Framingham Heart Study [41]. Here, SNP-set annotations are based on gene boundaries defined by the NCBI’s RefSeq database in the UCSC Genome Browser [42]. Unannotated SNPs located within the same genomic region were labeled as being within the “intergenic region” between two genes. These regions are labeled as *Gene1-Gene2* in the table. Posterior inclusion probabilities (PIP) for the input and hidden layer weights are derived by fitting the BANNs model on individual-level data. A SNP-set is considered enriched if it has a PIP $\gamma_w \geq 0.5$ (i.e., the “median probability model” threshold [47]). We also report the “top” associated SNP within each region and its corresponding PIP (γ_θ). The reference column details literature sources that have previously suggested some level of association between the each genomic region and the traits of interest. See Supplementary Tables 17 and 18 for the complete list of SNP and SNP-set level results. *: Multiple SNP-sets were tied for this ranking. ♣: SNPs and SNP-sets replicated in an independent analysis of ten thousand randomly sampled individuals of European ancestry from the UK Biobank [30].

References

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

1. Kang HM, Zaitlen NA, Wade CM, Kirby A, Heckerman D, Daly MJ, et al. Efficient control of population structure in model organism association mapping. *Genetics*. 2008;178(3):1709–1723. Available from: <http://www.genetics.org/content/178/3/1709.abstract>.
2. Kang HM, Sul JH, Service SK, Zaitlen NA, Kong Sy, Freimer NB, et al. Variance component model to account for sample structure in genome-wide association studies. *Nat Genet*. 2010;42(4):348–354. Available from: <http://dx.doi.org/10.1038/ng.548>.
3. Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population stratification in genome-wide association studies. *Nat Rev Genet*. 2010;11(7):459–463.
4. Lippert C, Listgarten J, Liu Y, Kadie CM, Davidson RI, Heckerman D. FaST linear mixed models for genome-wide association studies. *Nat Meth*. 2011;8(10):833–835. Available from: <http://dx.doi.org/10.1038/nmeth.1681>.
5. Korte A, Vilhjálmsson BJ, Segura V, Platt A, Long Q, Nordborg M. A mixed-model approach for genome-wide association studies of correlated traits in structured populations. *Nat Genet*. 2012;44(9):1066–1071. Available from: <https://pubmed.ncbi.nlm.nih.gov/22902788>.
6. Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies. *Nat Genet*. 2012;44(7):821–825.
7. Hayeck TJ, Zaitlen NA, Loh PR, Vilhjálmsson B, Pollack S, Gusev A, et al. Mixed model with correction for case-control ascertainment increases association power. *Am J Hum Genet*. 2015;96(5):720–730. Available from: <https://pubmed.ncbi.nlm.nih.gov/25892111>.
8. Heckerman D, Gurdasani D, Kadie C, Pomilla C, Carstensen T, Martin H, et al. Linear mixed model for heritability estimation that explicitly addresses environmental variation. *Proc Natl Acad Sci USA*. 2016;113(27):7377. Available from: <http://www.pnas.org/content/113/27/7377.abstract>.
9. Crawford L, Zeng P, Mukherjee S, Zhou X. Detecting epistasis with the marginal epistasis test in genetic mapping studies of quantitative traits. *PLoS Genet*. 2017;13(7):e1006869. Available from: <https://doi.org/10.1371/journal.pgen.1006869>.
10. Zeng P, Zhou X. Non-parametric genetic prediction of complex traits with latent Dirichlet process regression models. *Nat Comm*. 2017;8:456. Available from: <https://doi.org/10.1038/s41467-017-00470-2>.
11. Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for biobank-scale datasets. *Nat Genet*. 2018;50(7):906–908. Available from: <https://pubmed.ncbi.nlm.nih.gov/29892013>.
12. Jiang L, Zheng Z, Qi T, Kemper KE, Wray NR, Visscher PM, et al. A resource-efficient tool for mixed model association analysis of large-scale data. *Nat Genet*. 2019;51(12):1749–1755. Available from: <https://doi.org/10.1038/s41588-019-0530-8>.
13. Runcie DE, Crawford L. Fast and flexible linear mixed models for genome-wide genetics. *PLoS Genet*. 2019;15(2):e1007978. Available from: <https://doi.org/10.1371/journal.pgen.1007978>.

- 695 14. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the
696 missing heritability of complex diseases. *Nature*. 2009;461(7265):747–753. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/19812666>.
697
- 698 15. Visscher PM, Brown MA, McCarthy MI, Yang J. Five Years of GWAS Discovery. *Am J Hum*
699 *Genet*. 2012;90(1):7–24. Available from: <http://www.sciencedirect.com/science/article/pii/S0002929711005337>.
700
- 701 16. Zhou X, Carbonetto P, Stephens M. Polygenic modeling with Bayesian sparse linear mixed models.
702 *PLoS Genet*. 2013;9(2):e1003264.
- 703 17. Yang J, Zaitlen NA, Goddard ME, Visscher PM, Price AL. Advantages and pitfalls in the
704 application of mixed-model association methods. *Nat Genet*. 2014;46(2):100–106.
- 705 18. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, of the Psychiatric Genomics Consor-
706 tium SWG, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide
707 association studies. *Nat Genet*. 2015;47:291–295. Available from: <http://dx.doi.org/10.1038/ng.3211>.
708
- 709 19. Wray NR, Wijmenga C, Sullivan PF, Yang J, Visscher PM. Common disease is more complex
710 than implied by the core gene omnigenic model. *Cell*. 2018;173(7):1573–1580. Available from:
711 <https://doi.org/10.1016/j.cell.2018.05.051>.
- 712 20. Liu JZ, Mcrae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, et al. A versatile gene-based
713 test for genome-wide association studies. *Am J Hum Genet*. 2010;87(1):139–145.
- 714 21. Wu MC, Kraft P, Epstein MP, Taylor DM, Chanock SJ, Hunter DJ, et al. Powerful SNP-set
715 analysis for case-control genome-wide association studies. *Am J Hum Genet*. 2010;86(6):929–942.
- 716 22. Carbonetto P, Stephens M. Integrated enrichment analysis of variants and pathways in genome-
717 wide association studies indicates central role for IL-2 signaling genes in type 1 diabetes, and
718 cytokine signaling genes in Crohn’s disease. *PLoS Genet*. 2013;9(10):e1003770. Available from:
719 <https://doi.org/10.1371/journal.pgen.1003770>.
- 720 23. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of
721 GWAS data. *PLoS Comput Biol*. 2015;11(4):e1004219–. Available from: <https://doi.org/10.1371/journal.pcbi.1004219>.
722
- 723 24. Lamparter D, Marbach D, Rueedi R, Kutalik Z, Bergmann S. Fast and rigorous computa-
724 tion of gene and pathway scores from SNP-based summary statistics. *PLoS Comput Biol*.
725 2016;12(1):e1004714. Available from: <https://doi.org/10.1371/journal.pcbi.1004714>.
- 726 25. Nakka P, Raphael BJ, Ramachandran S. Gene and network analysis of common variants reveals
727 novel associations in multiple complex diseases. *Genetics*. 2016;204(2):783–798. Available from:
728 <http://www.genetics.org/content/204/2/783.abstract>.
- 729 26. Zhu X, Stephens M. Large-scale genome-wide enrichment analyses identify new trait-associated
730 genes and pathways across 31 human phenotypes. *Nat Comm*. 2018;9(1):4361.
- 731 27. Sun R, Hui S, Bader GD, Lin X, Kraft P. Powerful gene set analysis in GWAS with the Generalized
732 Berk-Jones statistic. *PLOS Genetics*. 2019;15(3):e1007530. Available from: <https://doi.org/10.1371/journal.pgen.1007530>.
733

- 734 28. Cheng W, Ramachandran S, Crawford L. Estimation of non-null SNP effect size distributions en-
735 ables the detection of enriched genes underlying complex traits. *PLoS Genet.* 2020;16(6):e1008855.
736 Available from: <https://doi.org/10.1371/journal.pgen.1008855>.
- 737 29. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature.* 2015;521(7553):436–444. Available from:
738 <https://doi.org/10.1038/nature14539>.
- 739 30. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource
740 with deep phenotyping and genomic data. *Nature.* 2018;562(7726):203–209. Available from:
741 <https://doi.org/10.1038/s41586-018-0579-z>.
- 742 31. Weissbrod O, Geiger D, Rosset S. Multikernel linear mixed models for complex phenotype predic-
743 tion. *Genome Res.* 2016;26(7):969–979. Available from: [http://genome.cshlp.org/content/
744 26/7/969.abstract](http://genome.cshlp.org/content/26/7/969.abstract).
- 745 32. Jiang Y, Reif JC. Modeling epistasis in genomic selection. *Genetics.* 2015;201:759–768.
- 746 33. Crawford L, Wood KC, Zhou X, Mukherjee S. Bayesian approximate kernel regression with
747 variable selection. *J Am Stat Assoc.* 2018;113(524):1710–1721.
- 748 34. Wahba G. Splines models for observational data. vol. 59 of Series in Applied Mathematics.
749 Philadelphia, PA: SIAM; 1990.
- 750 35. Crawford L, Flaxman SR, Runcie DE, West M. Variable prioritization in nonlinear black box
751 methods: A genetic association case study. *Ann Appl Stat.* 2019;13(2):958–989.
- 752 36. Holden M, Deng S, Wojnowski L, Kulle B. GSEA-SNP: applying gene set enrichment analysis to
753 SNP data from genome-wide association studies. *Bioinformatics.* 2008;24(23):2784–2785.
- 754 37. Benner C, Spencer CCA, Havulinna AS, Salomaa V, Ripatti S, Pirinen M. FINEMAP: efficient
755 variable selection using summary data from genome-wide association studies. *Bioinformatics.*
756 2016;32(10):1493–1501. Available from: <https://pubmed.ncbi.nlm.nih.gov/26773131>.
- 757 38. Hormozdiari F, van de Bunt M, Segrè AV, Li X, Joo JWJ, Bilow M, et al. Colocalization of GWAS
758 and eQTL signals detects target genes. *Am J Hum Genet.* 2016;99(6):1245–1260. Available from:
759 <https://doi.org/10.1016/j.ajhg.2016.10.003>.
- 760 39. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection
761 in regression, with application to genetic fine-mapping; 2019. *BioRxiv.* Available from: [http:
762 //biorxiv.org/content/early/2019/07/29/501114.abstract](http://biorxiv.org/content/early/2019/07/29/501114.abstract).
- 763 40. Valdar W, Solberg LC, Gauguier D, Burnett S, Klenerman P, Cookson WO, et al. Genome-wide
764 genetic association of complex traits in heterogeneous stock mice. *Nat Genet.* 2006;38(8):879–887.
765 Available from: <http://dx.doi.org/10.1038/ng1840>.
- 766 41. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, et al. The Third
767 Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study:
768 design, recruitment, and initial examination. *Am J Epidemiol.* 2007;165(11):1328–1335.
- 769 42. Pruitt KD, Tatusova T, Maglott DR. NCBI Reference Sequence (RefSeq): a curated non-
770 redundant sequence database of genomes, transcripts and proteins. *Nucleic Acids Res.*
771 2005;33(Database issue):D501–4.
- 772 43. Moser G, Lee SH, Hayes BJ, Goddard ME, Wray NR, Visscher PM. Simultaneous discovery,
773 estimation and prediction analysis of complex traits using a Bayesian mixture model. *PLoS*
774 *Genet.* 2015;11(4):e1004969. Available from: <https://pubmed.ncbi.nlm.nih.gov/25849665>.

- 775 44. Zhang Y, Qi G, Park JH, Chatterjee N. Estimation of complex effect-size distributions using
776 summary-level statistics from genome-wide association studies across 32 complex traits. *Nat*
777 *Genet.* 2018;50(9):1318–1326.
- 778 45. Lloyd-Jones LR, Zeng J, Sidorenko J, Yengo L, Moser G, Kemper KE, et al. Improved polygenic
779 prediction by Bayesian multiple regression on summary statistics. *Nat Comm.* 2019;10(1):5086.
780 Available from: <https://doi.org/10.1038/s41467-019-12653-0>.
- 781 46. Carbonetto P, Stephens M. Scalable variational inference for Bayesian variable selection in re-
782 gression, and its accuracy in genetic association studies. *Bayesian Anal.* 2012;7(1):73–108.
- 783 47. Barbieri MM, Berger JO. Optimal predictive model selection. *Ann Statist.* 2004;32(3):870–897.
784 Available from: <http://projecteuclid.org/euclid.aos/1085408489>.
- 785 48. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. Optimal unified
786 approach for rare-variant association testing with application to small-sample case-control whole-
787 exome sequencing studies. *Am J Hum Genet.* 2012;91(2):224–237. Available from: [http://www.](http://www.sciencedirect.com/science/article/pii/S0002929712003163)
788 [sciencedirect.com/science/article/pii/S0002929712003163](http://www.sciencedirect.com/science/article/pii/S0002929712003163).
- 789 49. Berk RH, Jones DH. Goodness-of-fit test statistics that dominate the Kolmogorov statis-
790 tics. *Z Wahrsch Verw Gebiete.* 1979;47(1):47–59. Available from: [https://doi.org/10.1007/](https://doi.org/10.1007/BF00533250)
791 [BF00533250](https://doi.org/10.1007/BF00533250).
- 792 50. Zhu X, Stephens M. Bayesian large-scale multiple regression with summary statistics from
793 genome-wide association studies. *Ann Appl Stat.* 2017;11(3):1561–1592. Available from: [https:](https://projecteuclid.org:443/euclid.aoas/1507168840)
794 [//projecteuclid.org:443/euclid.aoas/1507168840](https://projecteuclid.org:443/euclid.aoas/1507168840).
- 795 51. Blei DM, Kucukelbir A, McAuliffe JD. Variational inference: A review for statisticians. *J Am*
796 *Stat Assoc.* 2017;112(518):859–877.
- 797 52. Giordano R, Broderick T, Jordan MI. Covariances, robustness and variational bayes. *J Mach*
798 *Learn Res.* 2018;19(1):1981–2029.
- 799 53. Guan Y, Stephens M. Bayesian variable selection regression for genome-wide association studies
800 and other large-scale problems. *Ann Appl Stat.* 2011;5(3):1780–1815. Available from: [https:](https://projecteuclid.org:443/euclid.aoas/1318514285)
801 [//projecteuclid.org:443/euclid.aoas/1318514285](https://projecteuclid.org:443/euclid.aoas/1318514285).
- 802 54. Bult CJ, Blake JA, Smith CL, Kadin JA, Richardson JE. Mouse Genome Database (MGD).
803 *Nucleic Acids Res.* 2019;47(D1):D801–D806.
- 804 55. Chen X, McClusky R, Chen J, Beaven SW, Tontonoz P, Arnold AP, et al. The number of
805 X chromosomes causes sex differences in adiposity in mice. *PLoS Genet.* 2012;8(5):e1002709.
806 Available from: <https://doi.org/10.1371/journal.pgen.1002709>.
- 807 56. Strakova J, Kamdar F, Kulhanek D, Razzoli M, Garry DJ, Ervasti JM, et al. Integrative effects
808 of dystrophin loss on metabolic function of the mdx mouse. *Scientific Rep.* 2018;8(1):13624.
809 Available from: <https://pubmed.ncbi.nlm.nih.gov/30206270>.
- 810 57. Lotta LA, Mokrosiński J, Mendes de Oliveira E, Li C, Sharp SJ, Luan J, et al. Human gain-of-
811 function MC4R variants show signaling bias and protect against obesity. *Cell.* 2019;177(3):597–
812 607.
- 813 58. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and col-
814 laborative HTML5 gene list enrichment analysis tool. *BMC Bioinform.* 2013;14(1):128. Available
815 from: <https://doi.org/10.1186/1471-2105-14-128>.

- 816 59. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr:
817 a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.*
818 2016;44(W1):W90–W97. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/27141961>.
- 819 60. Saxena R, Voight BF, Lyssenko V, Burt NP, de Bakker PIW, Chen H, et al. Genome-
820 wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science.*
821 2007;316(5829):1331–1336.
- 822 61. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J, et al. Genome-wide
823 association analysis of metabolic traits in a birth cohort from a founder population. *Nat Genet.*
824 2009;41(1):35–46. Available from: <https://doi.org/10.1038/ng.271>.
- 825 62. Ko A, Cantor RM, Weissglas-Volkov D, Nikkola E, Reddy PMVL, Sinsheimer JS, et al.
826 Amerindian-specific regions under positive selection harbour new lipid variants in Latinos. *Nat*
827 *Comm.* 2014;5(1):3983. Available from: <https://doi.org/10.1038/ncomms4983>.
- 828 63. Hebbar P, Nizam R, Melhem M, Alkayal F, Elkum N, John SE, et al. Genome-wide association
829 study identifies novel recessive genetic variants for high TGs in an Arab population. *J Lipid Res.*
830 2018;59(10):1951–1966.
- 831 64. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, et al. LDL-
832 cholesterol concentrations: a genome-wide association study. *Lancet.* 2008;371(9611):483–491.
833 Available from: <https://pubmed.ncbi.nlm.nih.gov/18262040>.
- 834 65. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific
835 haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics.*
836 2015;31(21):3555–3557. Available from: <https://pubmed.ncbi.nlm.nih.gov/26139635>.
- 837 66. Paré G, Mao S, Deng WQ. A machine-learning heuristic to improve gene score prediction of
838 polygenic traits. *Scientific Rep.* 2017;7(1):12665. Available from: <https://doi.org/10.1038/s41598-017-13056-1>.
839
- 840 67. Kim BJ, Kim SH. Prediction of inherited genomic susceptibility to 20 common cancer types by a
841 supervised machine-learning method. *Proc Natl Acad Sci USA.* 2018;115(6):1322–1327. Available
842 from: <http://www.pnas.org/content/115/6/1322.abstract>.
- 843 68. Ho DSW, Schierding W, Wake M, Saffery R, O’Sullivan J. Machine learning SNP based prediction
844 for precision medicine. *Front Genet.* 2019;10:267. Available from: <https://www.frontiersin.org/article/10.3389/fgene.2019.00267>.
845
- 846 69. Jonsson BA, Bjornsdottir G, Thorgeirsson TE, Ellingsen LM, Walters GB, Gudbjartsson DF,
847 et al. Brain age prediction using deep learning uncovers associated sequence variants. *Nat Comm.*
848 2019;10(1):5409. Available from: <https://doi.org/10.1038/s41467-019-13163-9>.
- 849 70. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, et al. Obesity-
850 associated variants within FTO form long-range functional connections with IRX3. *Nature.*
851 2014;507(7492):371–375.
- 852 71. Claussnitzer M, Dankel SN, Kim KH, Quon G, Meuleman W, Haugen C, et al. FTO Obesity
853 Variant Circuitry and Adipocyte Browning in Humans. *N Engl J Med.* 2015;373(10):895–907.
854 Available from: <https://doi.org/10.1056/NEJMoa1502214>.
- 855 72. Kaess B, Fischer M, Baessler A, Stark K, Huber F, Kremer W, et al. The lipoprotein subfraction
856 profile: heritability and identification of quantitative trait loci. *J Lipid Res.* 2008;49(4):715–723.

- 857 73. Zhang C, Shahbaba B, Zhao H. Variational Hamiltonian monte carlo via score matching.
858 Bayesian Anal. 2018;13(2):485–506. Available from: [https://projecteuclid.org:443/euclid.
859 ba/1500948232](https://projecteuclid.org:443/euclid.ba/1500948232).
- 860 74. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1-
861 responsive genes involved in oxidative phosphorylation are coordinately downregulated in human
862 diabetes. Nat Genet. 2003;34(3):267–273. Available from: <https://doi.org/10.1038/ng1180>.
- 863 75. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene
864 set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression
865 profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. Available from: [http://www.
866 pnas.org/content/102/43/15545.abstract](http://www.pnas.org/content/102/43/15545.abstract).
- 867 76. Runcie D, Cheng H, Crawford L. Mega-scale linear mixed models for genomic predictions with
868 thousands of traits. bioRxiv. 2020;p. 2020.05.26.116814. Available from: [http://biorxiv.org/
869 content/early/2020/05/29/2020.05.26.116814.abstract](http://biorxiv.org/content/early/2020/05/29/2020.05.26.116814.abstract).
- 870 77. Zhou X, Stephens M. Efficient multivariate linear mixed model algorithms for genome-wide
871 association studies. Nat Meth. 2014;11(4):407–409. Available from: [https://pubmed.ncbi.nlm.
872 nih.gov/24531419](https://pubmed.ncbi.nlm.nih.gov/24531419).
- 873 78. Louizos C, Welling M. Structured and Efficient Variational Deep Learning with Matrix Gaussian
874 Posteriors. In: Proceedings of the 33rd International Conference on International Conference on
875 Machine Learning - Volume 48. ICML'16. JMLR.org; 2016. p. 1708–1716.
- 876 79. Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat
877 Assoc. 1993;88(421):9–25. Available from: www.jstor.org/stable/2290687.
- 878 80. Breslow NE, Lin X. Bias correction in generalised linear mixed models with a single component of
879 dispersion. Biometrika. 1995 2020/06/24/;82(1):81–91. Available from: [www.jstor.org/stable/
880 2337629](http://www.jstor.org/stable/2337629).
- 881 81. Lin X, Breslow NE. Bias correction in generalized linear mixed models with multiple compo-
882 nents of dispersion. J Am Stat Assoc. 1996;91(435):1007–1016. Available from: [www.jstor.org/
883 stable/2291720](http://www.jstor.org/stable/2291720).
- 884 82. Sun S, Zhu J, Mozaffari S, Ober C, Chen M, Zhou X. Heritability estimation and differential
885 analysis of count data with generalized linear mixed models in genomic sequencing studies. Bioin-
886 formatics. 2019;35(3):487–496. Available from: <https://pubmed.ncbi.nlm.nih.gov/30020412>.
- 887 83. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from
888 genome-wide association studies. Am J Hum Genet. 2011;88(3):294–305. Available from: [https:
889 //pubmed.ncbi.nlm.nih.gov/21376301](https://pubmed.ncbi.nlm.nih.gov/21376301).
- 890 84. Golan D, Lander ES, Rosset S. Measuring missing heritability: Inferring the contribution of
891 common variants. Proc Natl Acad Sci USA. 2014;111(49):5272–5281. Available from: [http:
892 //www.pnas.org/content/111/49/E5272.abstract](http://www.pnas.org/content/111/49/E5272.abstract).
- 893 85. Weissbrod O, Lippert C, Geiger D, Heckerman D. Accurate liability estimation improves power
894 in ascertained case-control studies. Nat Meth. 2015;12(4):332–334. Available from: [https://
895 doi.org/10.1038/nmeth.3285](https://doi.org/10.1038/nmeth.3285).
- 896 86. Xu B, Wang N, Chen T, Li M. Empirical evaluation of rectified activations in convolutional
897 network; 2015. ArXiv.

- 898 87. Wang L, Zhang B, Wolfinger RD, Chen X. An integrated approach for the analysis of biological
899 pathways using mixed models. *PLoS Genet.* 2008;4(7):e1000115. Available from: <https://doi.org/10.1371/journal.pgen.1000115>.
900
- 901 88. Califano A, Butte AJ, Friend S, Ideker T, Schadt E. Leveraging models of cell regulation and
902 GWAS data in integrative network-based association studies. *Nat Genet.* 2012;44(8):841–847.
903 Available from: <https://doi.org/10.1038/ng.2355>.
- 904 89. Yang J, Fritsche LG, Zhou X, Abecasis G, Consortium IARMDG. A scalable Bayesian method
905 for integrating functional information in genome-wide association studies. *Am J Hum Genet.*
906 2017;101(3):404–416.
- 907 90. Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic
908 Functional Enrichment to Improve GWAS Power. *Am J Hum Genet.* 2019;104(1):65–75. Available
909 from: <https://pubmed.ncbi.nlm.nih.gov/30595370>.
- 910 91. Srivastava N, Hinton G, Krizhevsky A, Sutskever I, Salakhutdinov R. Dropout: a simple way to
911 prevent neural networks from overfitting. *J Mach Learn Res.* 2014;15(1):1929–1958.
- 912 92. Wand MP, Ormerod JT, Padoan SA, Frühwirth R. Mean field variational Bayes for elaborate
913 distributions. *Bayesian Anal.* 2011;6(4):847–900.
- 914 93. Hoeting JA, Madigan D, Raftery AE, Volinsky CT. Bayesian model averaging: a tutorial
915 (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors.
916 *Statist Sci.* 1999;14(4):382–417. Available from: [https://projecteuclid.org:443/euclid.ss/
917 1009212519](https://projecteuclid.org:443/euclid.ss/1009212519).
- 918 94. Hormozdiari F, Kostem E, Kang EY, Pasaniuc B, Eskin E. Identifying causal variants at loci
919 with multiple signals of association. *Genetics.* 2014;198(2):497–508. Available from: <https://pubmed.ncbi.nlm.nih.gov/25104515>.
920
- 921 95. Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, et al. Variation in the
922 glucose transporter gene SLC2A2 is associated with glycemic response to metformin. *Nat Genet.*
923 2016;48(9):1055–1059. Available from: <https://pubmed.ncbi.nlm.nih.gov/27500523>.
- 924 96. Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+
925 T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients
926 with systemic lupus erythematosus. *Arthritis Rheum.* 2005;52(1):201–211.
- 927 97. Li H, Adamopoulos IE, Moulton VR, Stillman IE, Herbert Z, Moon JJ, et al. Systemic lupus
928 erythematosus favors the generation of IL-17 producing double negative T cells. *Nat Comm.*
929 2020;11(1):2859. Available from: <https://doi.org/10.1038/s41467-020-16636-4>.
- 930 98. Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus
931 pathogenesis and therapy. *Nat Rev Rheumatol.* 2020;16(2):100–112. Available from: <https://doi.org/10.1038/s41584-019-0356-x>.
932
- 933 99. Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE, et al. A genetic risk
934 factor for periodic limb movements in sleep. *N Engl J Med.* 2007;357(7):639–647.
- 935 100. Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide
936 association study of restless legs syndrome identifies common variants in three genomic regions.
937 *Nat Genet.* 2007;39(8):1000–1006.

- 938 101. Vaithilingam DS, Antao V, Kakis G. Regulation of polyunsaturated fat induced postprandial
939 hypercholesterolemia by a novel gene Phc-2. *Mol Cell Biochem.* 1994;130(1):67–74.
- 940 102. Silver M, Chen P, Li R, Cheng CY, Wong TY, Tai ES, et al. Pathways-Driven Sparse Regression
941 Identifies Pathways and Genes Associated with High-Density Lipoprotein Cholesterol in Two
942 Asian Cohorts. *PLoS Genet.* 2013;9(11):e1003939. Available from: [https://doi.org/10.1371/
943 journal.pgen.1003939](https://doi.org/10.1371/journal.pgen.1003939).
- 944 103. Cui C, Chatterjee B, Lozito TP, Zhang Z, Francis RJ, Yagi H, et al. Wdpcp, a PCP Pro-
945 tein Required for Ciliogenesis, Regulates Directional Cell Migration and Cell Polarity by Di-
946 rect Modulation of the Actin Cytoskeleton. *PLoS Biol.* 2013;11(11):e1001720. Available from:
947 <https://doi.org/10.1371/journal.pbio.1001720>.
- 948 104. Wang DX, Kaur Y, Alyass A, Meyre D. A candidate-gene approach identifies novel associa-
949 tions between common variants in/near syndromic obesity genes and BMI in pediatric and adult
950 European populations. *Diabetes.* 2019;68(4):724–732.
- 951 105. Okazaki Y, Furuno M, Kasukawa T, Adachi J, Bono H, Kondo S, et al. Analysis of the
952 mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. *Nature.*
953 2002;420(6915):563–573. Available from: <https://doi.org/10.1038/nature01266>.
- 954 106. Hansen GM, Markesich DC, Burnett MB, Zhu Q, Dionne KM, Richter LJ, et al. Large-scale gene
955 trapping in C57BL/6N mouse embryonic stem cells. *Genome Res.* 2008;18(10):1670–1679.
- 956 107. Diez-Roux G, Banfi S, Sultan M, Geffers L, Anand S, Rozado D, et al. A High-Resolution
957 Anatomical Atlas of the Transcriptome in the Mouse Embryo. *PLoS Biol.* 2011;9(1):e1000582.
958 Available from: <https://doi.org/10.1371/journal.pbio.1000582>.
- 959 108. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, et al. A conditional knockout
960 resource for the genome-wide study of mouse gene function. *Nature.* 2011;474(7351):337–342.
961 Available from: <https://doi.org/10.1038/nature10163>.
- 962 109. Klebig ML, Wall MD, Potter MD, Rowe EL, Carpenter DA, Rinchik EM. Mutations in the
963 clathrin-assembly gene *Picalm* are responsible for the hematopoietic and iron
964 metabolism abnormalities in *fit1* mice. *Proc Natl Acad Sci USA.* 2003;100(14):8360.
965 Available from: <http://www.pnas.org/content/100/14/8360.abstract>.
- 966 110. Lin H, Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF.
967 *Nature.* 1995;376(6537):263–267.
- 968 111. Laramie JM, Wilk JB, Williamson SL, Nagle MW, Latourelle JC, Tobin JE, et al. Multiple genes
969 influence BMI on chromosome 7q31-34: the NHLBI Family Heart Study. *Obesity (Silver Spring).*
970 2009;17(12):2182–2189.
- 971 112. Lichenstein SD, Jones BL, O'Brien JW, Zezza N, Stiffler S, Holmes B, et al. Familial risk for
972 alcohol dependence and developmental changes in BMI: the moderating influence of addiction and
973 obesity genes. *Pharmacogenomics.* 2014;15(10):1311–1321. Available from: [https://pubmed.
974 ncbi.nlm.nih.gov/25155933](https://pubmed.ncbi.nlm.nih.gov/25155933).
- 975 113. Steen VM, Nepal C, Ersland KM, Holdhus R, Nævdal M, Ratvik SM, et al. Neuropsycholo-
976 gical deficits in mice depleted of the schizophrenia susceptibility gene CSMD1. *PLoS One.*
977 2013;8(11):e79501.

- 978 114. Tennant BR, Vanderkruk B, Dhillon J, Dai D, Verchere CB, Hoffman BG. Myt3 suppression
979 sensitizes islet cells to high glucose-induced cell death via Bim induction. *Cell Death Dis.*
980 2016;7(5):e2233–e2233. Available from: <https://doi.org/10.1038/cddis.2016.141>.
- 981 115. Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, et al. Genetics of blood
982 lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. *Nat Genet.*
983 2018;50(11):1514–1523. Available from: <https://doi.org/10.1038/s41588-018-0222-9>.
- 984 116. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, et al. Mapping the Genetic Ar-
985 chitecture of Gene Expression in Human Liver. *PLoS Biol.* 2008;6(5):e107. Available from:
986 <https://doi.org/10.1371/journal.pbio.0060107>.
- 987 117. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci
988 that influence lipid concentrations and risk of coronary artery disease. *Nat Genet.* 2008;40(2):161–
989 169. Available from: <https://doi.org/10.1038/ng.76>.
- 990 118. Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, et al. The
991 impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quan-
992 titative change. *npj Genom Med.* 2020;5(1):1. Available from: <https://doi.org/10.1038/s41525-019-0109-4>.
- 994 119. Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, et al. Gene-centric association
995 signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. *Am J Hum Genet.*
996 2009;85(5):628–642. Available from: <http://www.sciencedirect.com/science/article/pii/S0002929709004698>.
- 998 120. Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, et al. Pharmacogenetic
999 meta-analysis of genome-wide association studies of LDL cholesterol response to statins. *Nat*
1000 *Comm.* 2014;5(1):5068. Available from: <https://doi.org/10.1038/ncomms6068>.
- 1001 121. Mo X, Lei S, Zhang Y, Zhang H. Genome-wide enrichment of m6A-associated single-nucleotide
1002 polymorphisms in the lipid loci. *Pharmacogenomics J.* 2019;19(4):347–357. Available from:
1003 <https://doi.org/10.1038/s41397-018-0055-z>.
- 1004 122. Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, et al. Exome-wide association
1005 study of plasma lipids in ~300,000 individuals. *Nat Genet.* 2017;49(12):1758–1766. Available from:
1006 <https://pubmed.ncbi.nlm.nih.gov/29083408>.
- 1007 123. Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al.
1008 Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk
1009 of coronary heart disease: A multivariable Mendelian randomisation analysis. *PLoS Med.*
1010 2020;17(3):e1003062. Available from: <https://doi.org/10.1371/journal.pmed.1003062>.